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ABSTRAcr

The results of our personal studies of alpha-I-protease inhibitor
(APi, forrrerly terned alpha-I-antitrypsin), the major inhibitor of

protease in extracellular fluids, are presented in this dissertation.
In the first chapter, we describe techniques used for APi quantitation and determination of Pi phenotypes.

After a brief review of the

available tedhniques, we report several ~rovements on our original
technique of Pi phenotyping using thin-layer isoelectric focusing.
Particular attention is given to biodherndcal and Lrnmunological methods
for verification of the results obtained t¥ isoelectric fOQlsing. Three
corrplenentary techniques are reported: protease prote, crossed imnunoelectrophoresis, and print ~ofixation. Analysis of the results from
print Lmmunofixation, using ~crodensitomet~, is of special interest.
In the seoond chapter, the alleles and phenotypes of the pi system
We report a detailed study of the distribution of Pi
phenotypes in two different populations and corrpare our results with

are described.

those previously reported in the literature, including more than 30,000
subjects. We also correlate serum APi levels with the various phenotypes. Our results derronstrate the existence of three new allele
products -- Me, Mb, and 12- In addition, we report that serum levels of
APi are slightly elevated in subjects with the Mb or Me allele, whereas
a marked reduction is associated with the e~ression of the I allele.
An additional study oonCErning Pi phenotype determination in oord blood
is presented, and the origin of the pattern of APi in newborns is
disoossed.

The

~ortance

of APi as a genetic rrarker is enphasized.

The third Chapter deals with the structure and biological role of
APi. After a sumrrary of the Olrrent knONledge on APi structure, we
report an original investigation concerning desialylation of APi. ~be
results suggest that sialic acids do not account for the rracroheterogeneity and polymorphism of APi. A study of the binding of elastase and
trypsin with APi shCMS that, in excess of APi, a stable corrplex is

formed.

In contrast, in excess of proteases the complex is dissociated,

with release of altered APi and of the protease previously inactivated.
In the fourth chapter, the clinical consequences of APi deficiency
are examined. The role of APi deficiency in pulrronary and liver dis-

eases is reviewed, and evidence for its predisposing role in nonatopic
asthma of infancy, herrochronatosis, juvenile chronic polyarthritis, and

squamous cell carcinoma is presented.

INTRODUCTION
'lnis dissertation is a compendium of studies, experience, and ideas
concerning the major protease inhibitor of extracellular fluids,
Alpha-I-Proteinase inhibitor (APi), the clinical interest of which
started with the study of deficient Pi phenotypes associated with
pulmonary diseases. This work presents the newest findings in
methodologic, genetic, biochemical and clinical studies, which
supplement an initial report presented in 1975 (1)
c·

The dissertation is divided in four parts, grouping the major
research areas by subject for greater clarity of presentation. The
first area deals with both macroheterogeneity and polymorphism as
defined py acid starch gel electrophoresis, an early method to study
these characteristics first reI,X>rted by Fagerhol (2). In 1974, Arnaud
et al. (3) reported that an identical microheterogeneity and
polymorphism was found when serum was sublldtted to isoelectric focusing
in a gradient of pH 4-6 (3), and Allen et ala (4) on a pH gradient
3.5-5. T'hese findings were soon confirmed by other investigators (5) in
1974. 1herefore, the first section is devoted to this area, and its
major emphasis is on new adjuncts to the technique of isoelectric
focusing which permit direct verification by three separate confirmatory
techniques for APi allele products. These include tests for
denaturation, ability to bind trypsin (6), and immunological methods,
particularly the print tmmunofixation technique developed specifically
for such studies (7)0
The second section deals with the genetics of the proteinase
inhibitor system, which in each individual is thought to be under the
control of two autosomal codominant alleles. . ~Dre than 25 different
alleles have been reported and more than 45 resulting phenotypes have
been clearly defined (1), although more than 325 combinations are
theoretically possible. A review is made of all world reports on Pi
types, and the results for distributions of types are compared with
those of two studies carried out as part of this research, one utilizing
serum from a French population and the other from Charleston, presumably
a more heterogenous population, comprising over 3000 people. In
addition r two new all~les which are variants of the common M allele are
described. These alleles have been designated respectively Mb and Me.
The relationship beteween phenotypes and serum APi values is:(eported in
588 healthy subjects, and two conclusions are drawn: the M variants Mb
. and Me are associated with APi levels slightly higher than the ones
associated ~ith MM phenotypes, and conversely, the I allele is
associated with decreased serum levels. The importance of APi as a
genetic marker is ewphasized. Preliminary population studies in cord
blood indicate that an accurate pi type can be interpreted from fresh
cord blood. In addition, the origin of slight variations in newborn
serum Pi patterns is discussed.

2

The third section includes studies on the structure and function of
the alpha-I-proteinase inhibitor, with special attention to the amino

acid and sugar composition of M and variant proteins. A new technique
for isolation and purification of APi is described. The role of the
sialic acids in ruacroheterogeneity and polymorphism of APi is discussed
on the basis of extensive studies of desialylation of MM, SS, and ZZ
variants from normal serum. Additional data concerning the binding of
trypsin and elastase to APi are reported. These indicate that, in
excess of proteolytic enzymes, the complex between APi and enzymes is
dissociated, leading to a denatured form of APi unable to exert a
protease binding role and the consequent release of the protease
previously inactivated.

In the last part, the clinical disorders associated with APi
deficien~ are presented.
Special attention is given to connective
tissue diseases, in which the role of APi deficiency appears to play an
increasingly ~rtant role. In this section, studies demonstrating a
high frequency of deficient pi phenotypes in nonatopic asthma of infants
are described, and a significant increase of the Z allele in juvenile
chronic polyarthritis and in squamous cell lung cancer is indicated. A
preliminary study also indicates that the presence of a deficient allele
is a predisposing factor in the onset of periodontal disease, and
conversely, that the M variant Me protects against its occurrence (8).
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HISroRICAL BACKGROUND

The first observations of antitryptic activity of serum were
reported in 1894 by Fermd and Pernossi (9) and in 1897 by Camus and Gley
(10). In 1900, Landsteiner noted that this activity was mainly
associated with the albumin fraction (11). A detailed study of
leukoproteases and antileukoproteases of mammals and birds was presented
in 1907 by Opie and Barker in one of the first issues of the Journal of
Experimental Medicine (12).
Following this descriptive step, the next stage mainly involved the
isolation and purification of the protein(s) responsible for this
activity. The first attempt was reported by Schmitz in 1968 (13).
Following the observation of Shulmann (14) demonstrating that, in fact .
two distinct inhibitors of protease were present in serum, Jacobsson
(15,16) separated them and further demonstrated that 90% was present in
the alpha-l globulin zone and 10% in the alpha-2 zone. Bundy and Mehl
(17) in 1959 reported partial characterization. In fact, in 1955,
Schultze already had isolated an alpha-l 3-5 glycoprotein from the
alpha-l globulin fraction and reported some physicocherodcal properties
without relating this fraction to proteins responsible for the
antiproteolytic activity of serum (18). Seven years later, he
established the identity between the major protease inhibitor of serum
and the alpha-l 3-5 glycoprotein and, with regard to its biological
properties, gave it the name "alpha-I-antitrypsin" (19).
In 1962, Laurel1 observed that sera of some patients when separated
by electrophoresis lacked the alpha-l band. These serum samples came
from a sanatorium, and case histories revealed that these subjects had
chronic obstructive lung diseases (20). In his dissertation thesis,
Eriksson in 1965 (21) reported the detailed clinical histo~ of patients
associating pulmonary emphysema and alpha-l-antitrypsin deficiency. The
same year, Fagerho1 and Braend (22), studying serum proteins with
discontinuous acid starch gel electrophoresis, discovered a ge~etically
deterfidned polymorphic system present in the prealbumin zone. TWo years
later, Fagerhol and Laurell (23) demonstrated that this system
corresponded to the mrrcroheterogeneity and polymorphism of
alpha-I-antitrypsin. They also demonstrated that the deficient state
was associated with the expression of a slow migration phenotype called
IIZZ", and proposed for this protein system the term "protease inhibitor t1
or "pi" (24).
In 1969, Sharp (25) reported the first case of the association of
APi deficien~ type ZZ and neonatal cirrhosis. He further demonstrated
(26) the accumulation in the liver of these patients of a material
immunologically related to APi. Lieberman (27) reported identical
findings in zz patients and in heterozygous NZ patients with pulmonary
diseases. In 1973, Talamo (28) reported the case of a patient with
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total serlUU deficiency, providing the existence of a "null" (-) allele
for the expression of APi.
According to the suggestion of Travis (29) that alpha-I-antitrypsin
is not an adequate name for this protein due to its major biological
role as an inhibitor of elastase and collagenase, the majority of the
authors working in this field agree to substitute a new designation
"alpha-I-protease inhibitor" (APi).
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Chapter 1
APi

QUAL~TITATIQ\J AL~

pi PHENOTY.PE DETERIlINATION;

TECHNICAL PARAt-1ErERS

The first techniques used to detect APi deficiency were only
quantitative, and based either on ~unological (30,31) or biological
(32) quantitation. They could define only three levels of serum APi:
normal, homozygous deficient, and intermediary (33). The discovery of
the pi system t in which several alleles and phenotypes proved to be
associated with serum APi deficiency, and the ability to characterize
their expression with accuracy using acid-starch gel (34) and later
isoelectric focusing (35,36), clearly improved the biochemical diagnosis
of deficient types, especially in the heterozygous state. At present,
APi level determinations are only a complernent of Pi typing I but they
retain an ~rtant role and should be done in parallel with the latter.
Each technique provides important information, and their combined
results are necessary for an accurate determination of the APi status.

I.

APi Measurement

Immunological techniques; These nethods are employed to
quantify APi levels in biological fluids by measuring the formation of
an antigen-antibody complex between APi and a specific antiserum raised
against pure APi. ·S.uch antibodies are ordinarily raised against APi
isolated from sera obtained from a pool of blood donors. The
quantitation of the precipitate formed is accomplished by three
techniques:
A.

1) Radial ~unodiffusion (RID). The fluid containing APi is
deposited in a hole made in agarose gel containing antibodies.
Diffusion of the serum produces a precipitate with the antibody, the
diameter of which is proportional to the amount of antigen deposited in
the hole.

2) Rocket electrophoresis. In this technique the antigen is drawn
into the gel py an electric force. As the antigen migrates, a
precipitate forms as a peak, and its height is proportional to the
amount of antigen present. The comparison between RID and rocket
techniques for the determination of APi levels in serum has been studied
in detail (37), and has shown that the Laurell-rocket techniques have
greater accuracy at lower cost. However, it needs an experienced
technician and necessitates the use of specialized electrophoretic
equipment. Recently, it has been proposed to used ~unonephelrnnetric
detection of APi in biological fluidsi this method should provide
equally good results (38).
The above techniques are based on the specificity of the anti-APi
antiserum. Commercially available antisera are normally of a quality
sufficient for this purpose. More precise techniques (immuno-

B

fluorescence), for which monospecificity of the antiserum is critical,
require further absorption of the antiserum. Such a result can be
obtained by absorbing a commercial antiserum on a Sepharose column on
which a pi null human serum has been attached (39). It must be pointed
out that comrrercially available antisera detect the M phenotype as well
as the other molecular forms, strongly suggesting an identity of the
major antigenic determinants present in both M and other allele
products. Attempts to produce a specific antiserum against the Z
variant have been unsucessful to date (4~), although Lieberman has
reported that Z phenotypes give, in immunodiffusion, a double ring
pattern specific for the phenotype (41). In fact, however, this
phenomenon seems to have been due to a particular batch of antiserum and
has not yet been reproduced.
B.. Biological techniques. These rrethods are based upon the fact
that APi represents over 90% of the antiprotease activity, including
antit~tic activity, of serum (42).
Therefore, the measurement of
serum trypsin inhibito~ capacity will allow the indirect measurement of
the APi. content of the serum. Several techniques have been reported,
using different substrates, either natural (gelatin, aiburrrrn) or
synthetic (benzoyl-arginine-ethyl ester, tosyl-arginine-methyl ester,
benzoyl-arginine-naphthylamide, benz6yl-arginine-p-nitroanilide)
(43,44). A very s~le technique, using the gelatin of photographic
emulsion, was reported by Fudenberg approximately 10 years ago and is
ve~ convenient for population screening due to its rapidity and low
cost (45). A more specific measurement of the inhibitory capacity of
serum related to its major biological role utilizes elastase as
proteolytic enzyme (46).

The major criticism that can be made of biological techniques is
their partial lack of specificity. Indeed, 90% of the inhibitory
capacity of serum is due to APi, but other inhibitory proteins, such as
alpha-2 macroglobulin, can -also be increased (42) and this increase can

mask a partial deficiency of APi. Due to the important overlap between
the different levels of different phenotypes, such a technical
imprecision could further confuse interpretation of results.
Nevertheless, biological techniques present a major advantage for they
measure a biological effect of APi and not antigenic sites. The trypsin
inhibito~ capacity of serum can be decreased without modification of
APi concentration which is estimated qy ~unological techniques in
order to detect possible denaturation of the inhibitor (47).

II.

pi Typing Techniques

A. Acid starch gel. In 1955, Smithies (48) introduced a new
support for zonal electrophoresis (molecular sieve) consisting of starch
gel. The separating performance of this support is based on the shape,
size and charge of the molecules. In 1959, Paulik (49) adapted the
starch gel technique to the study of the serum proteins using a
discontinuous buffer system. Modified by Fagerhol (50), this system
proved to separate a series of "prealbumin" bands, later identified as
APi (51). This technique employs an acidic gel, an acidic anodal
buffer, and a basic cathodal buffer (34,52) •. During rrdgration, the
basic buffer progresses to the anode and gives in the gel, a rise in pH
due to a moving boundary consecutive to the Kohlrausch effect, which is
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detected by ti1e formation of a migration front. The alkaline wave
during its progression is progressively buffered by the acidic radicals
of the gel buffer. A pH gradient is then progressively formed, as
indicated b¥ pH measurements on the surface of the acid-starch gels
(53). The separation principle in the technique of Fagerhol was in
actuality a type of isoelectric focusing, which explains the identical
distribution of the pi variants in both systems (35,54).
Although a basic reference technique during the past 6 years,
acid-starch gel presented various disadvantages: in addition to the
difficulty inherent in this technique, several points are very critical
and must be carefully checked, including the pH of the buffers, which
must be controlled before every run, the efficiency of cooling, and the
quality of starch. The best results were obtained, after assays of
several batches of starch, using Norwegian starch (gift of M.K.
Fagerhol) hydrolyzed in our laboratory. Moreover, the protein staining
was weak and minor components (like those of deficient phenotypes) could
not be readily seen on the-gel stain and had to be revealed by crossed
~unoelectrophoresis6
All these reasons could explain why this
technique has been used in no more than 15 laboratories in the world
with accurate results (55).
B. Isoelectric focusing: In 1973, Crawford (56) reported a new
technique for isolation of APi. This author noted that "pure n APi which
he isolated was microheterogeneous when examined by isoelectric
focusing. we then studied the pattern of other Pi types using
thin-layer isoelectric focusing, and our first results were presented in
January 1974 (35). More cowplete data were presented in Brugge
(Belgium) in Pay of the same year (57) r including development of crossed
~unoelectrophoresi~ from isoelectric focusing gels.
The isoelectric
focusing technique presents several advantages over acid-starch gel
technique, including rapidity of migration, the capacity to study
several samples (up to 75) s~ultaneously on the same run, a greater
resolution, and a better reproducibility. As an example, the Z bands,
often difficult to ascertain on direct staining of acid-starch gel,
cannot be missed, except by inadvertance, by an experienced investigator
on isoelectric focusing. All the phenotypes reported up to now using
acid-starch gel electrophoresis can be identified with this technique.
In addition, other allele products not separated on acid-starch gel
electrophoresis have been demonstrated by isoelectric focusing. They
include I2, ~fu, and Me (see Chapter 2). The technical requirements of
IEF, including the recent modifications that enabled us to describe
these new alleles, are shown in Table 1. A slightly different technique
using gels 1.3 rnm thick containing no sucrose is shown in the same
table. The staining and destaining steps are identical to those
reported previously (57). Identical results were soon obtained by other
investigators using similar or slightly modified isoelectric focusing
techniques (36,58,59(61).
Special attention must be given to the following points: The
purity of acrylw~ide is critical and better results are obtained using
recrystallized acrylamide (60). The polymerizing agent(s) are also
important. As modified from our previous techniques, we no longer use
T~~D, and we have decreased ammonium persulfate concentrations to only
8 rng/gel. we did not find any advantage to modified cathode solutions
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Table 1
Composition of thin-layer polyacrylamide gels
containing ampholines and rnagration conditions
A.

Thick gel (2 rom)

Acrylamide = 2.91 9
N N' Methylenebisacrylamide = 0.09 g
Sucrose ~ 7.4 9
Double distilled deionized water = 56 ml
Ampholines: 3.5 - 5: 0.5 ml
4.0 - 6: 2.5 m!
Arruuonium persulfate 1%: 1 m1
T = 5%; C = 3%; pH range = 3.5 - 5.5
B.

Thin gel (1 mm)

Acrylamide = 2.22 9
N N ' Methylenebisacrylarnide = 0.162 9

Double distilled deionized water = 18 ml
Ampholines: 3.5 - 5 = 2.0 ml
"N N N' N' Tetramethylethylenediarnine = 50 ul
Arruuonium persulfate 0.07% = 20 ml
T = 6%; C = 6.8%; pH range = 3.5 - 5

c.

Electrode solutions
For thick gel:

Cathode:
Anode:

For thin gel:

Cathode:
Anode:

D.

NaOH 1.0 Poi
H3P04 1.0 M

Ampholine 5.8, 0.4%
H3P04 1." M

Migration conditions

For thick gel:

35 watts for 3 hr

For thin gel:

20 watts for 30 min
25 watts for 25 min
30 watts for 10 rrdn
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using glycine or T~}£D {61}. The use of a power supply permitting the
delivery of constant power is, in our hands, the factor that most
improved the technique, permitting a much more regular rndgration without
any overheating. An efficient cooling system permits increased duration
of the migration, and therefore the gel is refrigerated by a
Lauaa-Brinkmann cooling syste~ that delivers a circulating water at a
temperature of 0o C. The temperature of the gel is +SoC. The use of
other stains (Coornassie G 250) did not improve in our hands the
differentiation of the bands. When larger pH ranges are necessary, we
use a thin gel (1.2-1.5 mm thick), the composition of which is indicated
in Table 2. A typical isoe1ectrofocusing run in a gradient of pH 4-6 is
indicated in Figure 1.

c.

Complementary techniques applied to isoelectric focusing:

1) Antigen-antibody crosssed immunoelectrophoresis. ~e report here
our own technique of crossed ~unoelectrophoresis( which includes
several technical improvements over the one we first described in 1974
(35) •

A solution of acrylamide (0.9%) and agarose (0.7%) (W/V) in
Barbital buffer 1 0.1 ["I, pH 8.8, containing 1 roM calcium lactate was

heated to boiling, and 21 ml of the solution was poured on a glass plate
(85 x 85 rum). After 15 min, at 4o C, the central part of the gel (32 x
85 ~~) was cut and removed. After completion of the isoelectrofocusing
run, a strip (90 x 4 rom) was cut in the central part of the migration
area of PAGIF and placed close to the edge of the acrylamide-agarose gel
plate. The central part of the plate and the strip were covered with 7
ml of the same acrylarnide-agarose solution to which a specific anti-APi
antiserm had been added.

After gelation, the :portion including the
PAGIF strip was carefully covered with a larger strip of
acrylamide-agarose, and the plate (inclusion close to the cathode) was
submitted to electrophoresis (70 rnA per plate for 6 he) on an LKB
Multiphor 2117-116 apparatus (LKB Application Note 85). Barbital buffer
0.1 ill, pH 8.8, was used as the vessel buffer. After washing overnight
in saline r the plates were dried, stained with Amido Black, and
destained.

The following points are critical for accurate results:

a) The relative amount of antigen and antibody is critical and can
produce peaks that are either too high (excess of antigen) or too small
(excess of antibody). According to the above procedure, an optimal
ratio is obtained when the serum used for the first dDmension is diluted
to 0.3 mg/ml APi, and when 150 ug of specific antiserrnn is added to the
7 ml of acrylamide-agarose filling the central part of the gel.
b) Inclusion of the PAGIF strip inside the gel gives us more
reproducible results than does application of the strip to the surface
of the gel as proposed by SOderholm (62). In addition, covering the
inclusion with a strip of acrylarnde-agarose prevents separation of the
gel at the inclusion and suppresses endosmotic flow.
c) The steps of the procedure must be performed as fast as possible
to avoid any diffusion of the already focused bands. Better results are
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, Table 2

Composition of thin-layer polyacrylamide gels containing ampholines
pH range 3.5 to 8 and migration conditions
A.

Gel composition (T

= 6%;

C

= 6.8%)

Acrylamide = 2.22 9
N N' Methylenebisacrylamide

= 0.162

9

Double distilled deionized water = 18 ml

Ampholines 3.5 - 5 = 1 ml

5.0 - 8 = 1 ml
N N N' Nt Tetramethylethylenediamine = 50 ul

Ammonium persulfate 0.07%
B.

Electrode solutions
Cathode = NaOH 1.0 M
Anode
= H3P04 1.0 N

c.

Migration conditions
20 watts for 30 min
25 watts for 25 min

310 watts for 15 min

= 20

ul

13

-.... -.

-~,

... -

.~-~

-

- .- --, .. ~

M

.

..

~

MZ

MZ

p

MP

p

MP

,. , ', ..·

Fig. 1.

1\1\

· :-~f ·

Typical results of Pi determinations using thin-layer
isoelectric focusing (anode at the top). (A) 24 different
ph2DOtypeS. CJ:he samples indicated with a question mark have
been further identified as I1 variants. (8) Detail of pi type
patterns
v

14

obtained when all the manipulation is performed at 4°C. The PAGIF strip
must be handled carefully to avoid marks left. by fingerprinting.

Examples of crossed liwnunoelectrophoresis performed with this
technique are shown in Figure 2.

2) Print immunofixation. After completion of electrofocusing runs,
gels were placed at 4°C. A strip of cellulose acetate (Sepraphore III,
GelrMn Instruments Co.) was soaked with specific antiserum and carefully
transferred onto the surface of the gel. The gel was incubated for 1 hr
at 220c and then a glass plate 'WaS put on top of the gel (still covered
with the cellulose acetate strip). A weight was placed on the glass
plate for 30 min to apply uniforTIl pressure. 1ne glass was then removed,

and the gel and strip were washed separately for 16 hr in three changes
of saline (2 liters each ti~me), stained with Coomassie Brilliant Blue
(R250) in methanol-water-acetic acid (5:5:1), and destained in
methanol-water-acetic acid (5:5:1).
prelirrdnary experiments indicated that for APi the patterns
obtained on the cellulose strips are much sharper than those from the
gel. Thus, the development of Lmmune complexes in the strips is of
great ~rtance. The fragility of cellulose acetate is critical. The
strip must be manipulated carefully and must not be touched directly.
For staining of the cellulose acetate strip one of its ends is attached
to a metallic clip and the strip was immersed no more than 6-8 times (10
sec each) in the staining solution and then immediately destained.
Bending or stretching of the strip must be avoided during these
manipulations. Excess staining will cause a dark background which makes
the patterns difficult to interpret.
A comparison of isoelectric focusing, crossed
irnrnunoelectrophoresis r and print immunofixation is shown in Figure 3.

D. Other technigpes: Several other techniques or modifications of
the existing techniques have been reported.
1) Modification of acid~starch gel technique. Thomas proposed a
tube technique (63) that did not see~ to possess significant advantages
over flat bed acid-starch gel electrophoresis. ~be other modifications
are mainly concerning buffers: Kueppers (64) uses an EDTA buffer, and
Cook (65) different concentrations in starch and buffers. A very
important improvement that was developed in the acid-starch gel
technique is obtained by Dnmunofixation as a second step. The patterns
are clearer and sharper, and this technique can be used as an
alternative to crossed immunoelectrophoresis, with the advantage of
immunofixation before the latter (66).
.
2) Agarose electrophoresis at pH 8.6. This technique, first
introduced by Laurell (67) and Fagerhol and Laurell (68) in combination
with crossed ~noelectrophoresis, permits separation of several
variants. It is eSp2cially useful to identify r-1S and MV phenotypes and
certain fast phenotypes. Its combination with bTImunofixation permitted
Johnson (69) to identify several M variants, although the problem of M
variants still requires a precise comparison and clear-cut nomenclature
(see Chapter 2).
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3)

Acid agarose gel electrophoresis.

Four years ago, Laurell and

Persson (7£a) reported a new technique which can be used in combination

with crossed ~unoelectrophoresis to identify several Pi variants.
Nevertheless, its advantages over acid-starch gel electrophoresis and
isoelectric focusing are not striking, and to our knowledge it has not
been used outside the laborato~ that described it.
4) Cellulose acetate electrophoresis. This method was recently
suggested by Harada (71). Its major advantage is facility.
E.

Pitfalls and Problems of Pi TYPing:

1) Serum alteration. APi is a very labile protein, and several
factors can alter its pattern both in isoelectric focusing and in
acid-starch gel. TWO kinds of modifications of Pi types are frequently
noted:
a) Fast migrating pattern. Two banos are super~posed on the
normal pattern, a band below M4 and a band above M6 (Fig. 4). This
pattern could easily be ildsinterpreted as a fast variant (72). A normal
pattern is restored after incubation of the serum for 20 rrdn with 2
drops of 5% B-rnercaptoethanol as suggested by Cook (65). The origin of
this denaturation is not known, nor why rrercaptoethanol treatment
restores a normal pattern, although it could involve a thiol-disulfide
interchange.
b) Slow migrating patterns. Additional slow bands can be seen in
stored sera that are not present in fresh samples. They are especially
confusing because they interfere with the position of the slow bands of
the deficient Sand Z phenotypes. Their multiplicity is clearly
revealed when print ~unofixation or crossed ~noelectrophoresis is
used as a second dimension, which demonstrates the existence of a serum
alteration. we found a high level (25%) of such alteration in a series
of sera from patients with IgA deficiencies (73). These sera had been
frozen and thawed several times for different purposes. All of them
(but none of the ones with clear-cut patterns) were found to be
contaminated by Lactobacillus sp. and Enterobacter aerogenes. To study
the effects of physical factors versus bacteriological factors
contributing to the deterioration of serum APi, sera of different
phenotypes were drawn aseptically and divided into aliquots. Repeated
freezing and thawing of sera and storage at +4oC for as long as one
month did not affect the phenotype. In contrast, contamination of
aliguots with the bacteria altered the serum samples, causing a change
in the pattern of APi in as short a time as 48 hr despite storage at
+4oC. The new pattern obtained after both accidental and artificial
contamination is probably due to the removal of sialic acid residues
from the APi I11C)lecule as suggested by Nyerowitz (74), for neither TIC
nor ~unologically reactive APi is modified, although the pattern is
modified. Some examples of such alteration are given in Figure 5.
'lhe above problems arise in the case of stored sera.. They
emphasize the importance of fresh serum samples for pi typing, or
aliquots obtained without any preservative agent and thawed only once
for the identification. One must emphasize that certain variant
phenotypes are very sensitive to alteration, especially those composing
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Alteration of pi r-l phenotype (fast pattern).
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A..ncx:1e at the

19

Fig. 5.

Comparison of crossed ~unoelectrophoresis (A,D) and print
immunofixation (B,E) obtained from altered f1 sera (slow
pattern). In C and F, print immunofixation of a normal H
control is given as reference. Note the shift in APi patterns
toward the cathode in case of serum alteration. This shift
could be confused for the presence of a slo,tl (deficient)
phenotype. In B,C,E,F, anode at the left. In A and D, first
dimension, anode at the left; second diIT2nsion, anode at the
top.
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the P and Z alleles (75). Other samples can be stored for several years
without deterioration. For example, the s@ne 8M standard (generous gift
of Dr. J.P. ~artin, INSERM U 72, Bois Guillaume, France) has been used
In our laboratory for more than three years.
F.

l·1icrodensi tometry:

This technique, permitting a quantitative determination of the
components of pi phenotypes, was first applied to APi phenotyping by
Allen (60). The pattern obtained from direct densitometry of
isoelectric focusing can be clearly superimposed on those obtained by
crossed bnffiunoelectrophoresis from focusing of the same gels (Fig. 6).
Nevertheless, interference of the pi types with other proteins,
including haptoglobin, Gc component, and other fast-migrating proteins
of isoelectric point between 4.5 and 5.5 (76), cannot be eliminated by
microdensitometric scan. This technique is of major interest when
applied to specific bands fixed in cellulose acetate strips after print
~unofixation, and the resolution of microdensitometry is much better
than that obtained ~ crossed immunoelectrophoresis (Fig. 6).
G. Suggested procedure to be applied for accurate determination of
APi status:
The recommended procedure is summarized in Table 3. Its complexity
arises from the need for clear separation of the different Pi types.
The increasing number of variants described, especially when studied
using isoe1ectric focusing, makes interpretation of Pi phenotypes rather
difficult. Although isoelectric focusing clearly has major advantages
over acid-starch gel electrophoresis, it has the inconvenience of its
advantages and, since it allows the differentiation of several variants'
not recognized before (see Chapter 3), it complicates the work of the
interpreter. For this reason we feel that pi determination must be
restricted to reference centers that possess the different techniques
suggested above, and are able to do them routinely, having a collection
of reference sera and being in contact with other specialized
investigators. In this context, Pi typing can be compared with other
genetic and immunological typing techniques such as Gn, Am, and HIA type
determinations. The association of some pi types with various diseases
increases the importance of their accurate determination. In addition,
the interest of using fresh serum samples and performing complementary
family studies is again emphasized.
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Table 3
Stepwise procedure applied to pi phenotype determination in

Suspected
serum
alteration

ser~~

Confirrred
-:2--5-8--+ serum
alteration

Normal

Known
phenotype - 4
Non-iwl

Deficient

2-3

Suspected
unknown
phenotype
5

6
7
9

I
Conf irm....oc1
1-4
new
phenotype

1

= isoelectr ic

Norrnal

Deficient

focusing

2 = print inununofixation, crossed immunoelectrophoresis, and/or protease probe

3 = comparison with standard pi t.YP'2S

= serum APi determination (immunological
5 = isoelectric focusing on fresh sample
4

and biological techniques)

6 ::: family studies
7 == acid-starco gel follo~yed by crossej immunoelectrophoresis
8 == treatment with rrercaptaethanol
9 = control by a reference laboratory
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Chapter 2
ALLELES AND PHENOTYPES OF THE

pi

SYSTEM

It is now established that two autosomal cooominant alleles code
for APi polymorphism, which is expressed in the individual as the Pi
phenotypes (77). Since the first report of Eriksson in 1965 (78) I more
than 25 alleles have been discovered, which are differentiated according
to their position in discontinuous acid-starch gel electrophoresis (79)
or after separation by isoelectric focusing techniques (80,81). The
alleles described to date are indicated in Table 4. Their
identification is still complicated, however, ~ the presence of the
so-called M variants (Table 5). Some of the alleles are associated with
decreased serum levels of APi (Table 6). In addition, a null variant
allele, Pi null or pi (-), has been described by Talamo (82), and
further reports have confirmed the existence of this allele in the
homozygous (83-85) or heterozygous state (86,87).

The expression of these alleles results in phenotypes. Only 45 of
the more than 400 possible combinations have been reported to date (88).
The allele combinations currently recognized are shown in Table 7. Two
reports have suggested that there may be linkage between pi phenotypes
and Gm allotypes present on ~unoglobulin gamma heavy chains (89 1 90),
but this question remains uncertain (91). Linkage between Pi and
erythrocyte alkaline phosphatase (ACPR) has also been proposed (92) but
has not been confirmed in a more recent study (93). In addition, we
have recently reported a departure from Hardy-Weinberg equilibrium in
sera obtained from a large population of blood donors and studied by
isoelectric focusing (94); and the transmission of the deficient alleles
(8 and Z) seems to be more ~rtant than that of the M allele (95).
These observations could indicate that the inheritance of the alleles of
the pi system is more complicated than the simple autosomal codominant
rroCie ..

I.

The M Variants
A.

hvidence for a common M variant, M Cathodal (Me):

Refinement

of the isoelectric focusing technique in our laboratories has enabled us
to recognize a variant of the M allele which is characterized by
duplication of all the bands constituting the mdcroheterogeneity. We
have called this variant M cathodal (Me) (96). It may be similar or
identical to other M variants, MB, ML, and M2 reported recently by
others (97-99). In addition, it is possible that the allele described
as N by Constans (100) could in fact correspond to the Me allele. The
distibution of this new allele varies between 10 and 15% in the previous
report of Hoffman (97) and 22% in our own studies (Table 8). we have
observed this allele in combination with the majority of the other
alleles (E,D,F,G1I,M,P,Q,S,V,W,X,Z) and in the homozygous state (McMc)
Some examples illustrating the pattern of this variant in different
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Table 4

Alleles of the pi system
Reference

Designation

B
C

D

11artin 1 J.P., Vandeville, D., Ropartz, C. Biomedicine 19:395-398,
1973.
Robinet-Levy, M. Quoted by Fagerhol, M.K. In: Protides of the
Biological Fluids (H. Peeters, Ed.) Pergamon Press, pp. 34-37,
1975.
Robinet-Levy, M., and Rieunier, M. Rev. Franc. Transfus. 15:61-72,
1972.

E
E2
F
G
I
L
M
N
S
V
W
W2
X

Y
Y2
Z
(-)

Fagerhol, M.K. Poumon Coeur 27:41~51, 1971.
Fagerhol, M.K. In: Protides of the Biological Fluids {H. Peeters,
Ed.) Pergamon Press, pp. 36-37, 1975.
Fagerhol, M.K., and Braend, H. Science 149:986-987, 1965
Fagerhol, M.K. Poumon Coeur 27:41-51, 1970.
Fagerhol, M.K. Acta Pathol. Microbicl. Scand. 70:421-428, 1967
Vandeville, D., Martin, J.P., and Ropartz, C. Humangenetik
21:33-38, 1974.
Fagerpolt M.K.; and Hauge, H.E. Vox Sang. 15:396-400,1968.
Cox, D.W., and Celhoffer, L. Can. J. Genet~~Cytoi. 16:297-301,
1974.
Fagerho1, M.K., and Hauge, H.E. Vox Sang. 15:396~400, 1968.
Fagerho1, M.K. Acta Pathol. Microbiol. Scand. 70:621-628, 1967.
Fagerhol, M.K., and Tenfjord, O.W. Acta Pathol. Microbial. Scand.
72:601-608, 1968.
Cook, P.J.L. Ann. Hum. Genet. (London) 38:275-287, 1975.
Eriksson, S., and Laurell, C.B. Acta Chern. Scand. 17(suppl. I}:
150-153, 1963.
~
Cook, P.J.L. Ann. Hum. Genet. (London) 38:275-287, 1975.
Cook, P.J.L. Ann. Hum. Genet. (London) 38:275-287, 1975.
Laurell, C.B., and Eriksson, S. Scand. J. Clin. Lab. Invest.
15:132-140, 1963.
Talamo, R.C., Langley, C.E., Reed, C.E., and V~kinol s. Science
181:70-71, 1973.

Tab1e 5

M Variants

Designation*

Characteristics

Frequency

M Baldwin

Deficient
(approx. 20%)

0.5-1%

Johnson, A.M. J. Lab. Clin. Med.
87:152-163, 1976.

MLarnb

Deficient
(approx. 20%)

2%

Johnson, A.M. J. Lab. Clin. Med .
87:152-163, 1976.

M Malton

Markedly deficient
(approx. 90%)

rare

Cox, D.W., In: Protides of Biological
Fluids (H. Peeters, Ed.) Pergamon Press,
pp. 375-378, 1975.

M Duarte

Markedly deficient

rare

Lieberman, J., Gaidulis, L. , Klotz I S.D.
AIDer. Rev. Resp. Dis. 113:31-36, 1976.

17%

Kueppers, F. Amer. J. Hum. Genet.
28:370-377, 1976.

20%

Frants, R.R., Eriksson, A.W.
26:435-440, 1976.

(approx. 90%)

Ml

Normal serum levels

M2

Reference

Hum. Hered.

Mn

Normal serum levels

10-15%

Van Den Broek, W.G.M., Hoffmann, J.J.M.L.,
nijkman, J.N. Hum. Genet. 34:17-22, 1976.

M Cathodal

Slightly increased
serum levels

20-25%

Arnaud, P., Chapuis-Cellier, C., Creyssel,
R. , Fudenberg l H.H. Clin. Res. 25:20A,
1977.

MB

Slightly increased
serum levels

5%

Chapuis-Cellier, e., Arnaud, P.
preparation, 1977.

*There is strong evidence that M Malton and

and N Cathodal probably are identical.

M

Duarte nay be identical.

in

Similarly, MIl M2,

Mn,

~

\,0
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Table 6

Deficient alleles and their

Alleles

Expression

Frequency

e~ression

(% of the M allele)

Reference
This study.

53%
0.3%

This study.

53%
Not reported

0.1%

Fagerhol, M.K., and Hauge,
Sang. 15:396-400, 1968.

s

72%

3-6%

Fagerhol, M.K., and Braend, M.
Science 149:186-187, 1965.

w

Not rep:>rted

0.02%

Fagerhol, M.K., and Tenfjord, D.W.
Acta Pathol. Microbial. Scand.
72:601-608, 1968.

z

15%

2.6%

Laurell, C.B., and Eriksson, S.
Scand. J. Clin. Lab. Invest.
15:132-140. 1963.

(-)

0%

<0.1%

H~E.

Vox.

Talamo, R.C., Langley, C.E. 1 Reed,
C.E., and Makino, S. Science
181:70-71, 1973.
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Table 7
pi alleles and resulting phenotypes

e El F

•

•

••

Fl G i l M MaMLMM N P S

•
• •
v W W1 X Y Y1 Z -

Pi

BCD

B

~-T~1-~~-+~~~-+~4-~~~~+-~~~

•

Y

•

The alleles are indicated on the abscissa and ordinate. Their
combination results in the corresponding phenotypes. Those
r eported in the literature or found in our laboratory are
i ndicated by black squares. In addition( the deficient alleles
are des ignated \Alith asterisks.
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Table 8

Distribution of Mb and Me in a population
of 1867 healthy Caucasian blood donors
HOITlOzygote

M

2.25

5.84

18.75

s

z

1.12

0.05

3.05

0.42

*The frequencies of ~ and MbMc are not reported due to the
difficulty of accurate differentiation between these phenotypes.
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combinations are shown in Figu~e 7. Me represents the most common
variant after Pi M. we have not directly compared Me with M Baldwin or
M Lamb, two M variants recently reported by Johnson (102), but M Lamb
is, in contrast to Me, associated with decreased levels of APi, and M
Baldwin is very unusual.
B.

The MB Variant:

The improved technical conditions have also

allowed recognition of another variant whose migration is slower than
that of M but faster than that of Me, and for which we propose the
designation MB- Some examples of this new allele are shown in Figure B.
A parallel study, conducted in France by c. Chapuis-Cellier, has
determined its distribution in a normal population (Table 8). Family
studies also conducted in France indicate that this allele is, as the
other alleles of the pi system, transmitted in the autosomal codominant
mode. The routine recognition of this allele requires, in addition to
precise technical conditions described above,- special expertise in
interpretation to prevent its confusion with M or Me. Commercial
production of Arnpholine of a more restricted pH range would facilitate
the recognition of this variant allele.
II.

Distribution of Pi

Phenot~s

and Alleles 1n Normal Populations

Several investigations conducted in different countries are
reviewed in Table 9 (1~3-129). They represent serum samples obtained
from more than 30,000 subjects. The distribution of the corresponding
allele frequencies is given in Table 10. Attempts to compare the
results obtained in these reports are hindered by the relatively
insensitive techniques employed in earlier studies and the different
population groups selected, i.e., healthy blood donors, students, or
random populations. Nevertheless, an overall picture emerges from these
results. First, the ~rtance of ethnic variations between the
populations according to their origin is readily apparent, i.e., the
high frequen~ of S alleles and phenotypes in Spain and Portugal
(118,121,122), and the scarcity of variant phenoptypes in Blacks and
Asians (112,118,123). We have already published our results of pi
phenotypes in two different populations (105,109) and present here two
original studies (Table 11), one conducted on sera from a region of
France (presumably a relatively homogeneous population) and using
healthy blood donors, the other in south Carolina, based on the study of
several population groups. In these studies, M variants have been
listed as M, to permit comparison with previous reports. It should be
emphasized that populations studied using isoelectric focusing
demonstrate a greater frequency of variant alleles due to the higher
resolving power of this technique when compared with that of acid-starch
gel electrophoresis.
III.

Correlation Between pi Phenotypes and Serum Values of APi

In the second series of pi phenotypes in Lyon, we undertook
systematic correlation of serlli~ APi values with the phenotypes. The
results aLe indicated in Table 12. The expected values for the
different alleles are shown as a percentage of APi values. These
results'are in good agreement with those reported in the literature,
especiallY for the Z allele (130,131). It can be observed that the
values obtained from serum APi in ZZ patients, particularly in those
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",

Fig. 7.

Patterns of the Mc variant (anode at the top). Note the
slight displacement of the Nc allele product both in
heterozygotes (1\1Ivlc, ~1cS) and in the homozygous state ([\'1c).
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c
b

Fig. 8.

Q

Patterns of the Nb variant (anode at the top). The rvIbQ
phenotype was provided by the courtesy of Dr. J.A. Pierce
(St. Louis, Mo.).

TABLE 9.
PHENOTYPES

KELLERMAN

REF
106

Pi PHENOTYPES IN THE LITERATURE

ETHNICITY

YEAR

ICELANDERS

1970

GERMANS
GREEKS
HUNGARIAl~S

VAL'lDEVILLE
MORIN
ARNAUD
ARNAUD
HOFFMAN

COOK

107
108
109
105
97
110

IRANIANS
PAKISTANIANS
INDIANS
KOREANS
NEGROES
BLACK BANTU
FRENCH
FRENCH
FINNISH
DUTCHS
BLACKS
INDIANS

1974
1975
1977
1977
1976
1975

ARAB

ORIENTAL

WEBB
McDERMID
THOMAS
KIRK
VANDEVILLE

114
115

HARADA

116

FAG ERH OL
COOK

GOEDDE
FAGERHOL

McDERMID
FERTAKIS

III
112

NEW YORK/USA
INDONESIAN

113

GERMANS
NEW GUINEA
FRENCH
AMER. INDIAN

103
110
117

II?

119

MARTIN
LIEBERMAN

120
121;
122
12'3

BLUNDELL
PIERCE
FAGERHOL

124
125
104

GEADA

McDERMID
ROBINET-LEVY
GOEDDE
FAGERHOL
ARVILOMMI
TOTAL

126
127
128
104
129

JAPANESE

AINU
USA
NORWEGIANS
CAUCA.SIANS
GERMANS
SPANISH
PORTUGESE
EUROPE
LATIN-AMERICA
ASIA
S. AFR. INDIANS
GREEKS
PORTUGESE
PORTUGESE
CALIF/USA/HHITE
BLACK
MEXICAN
IRISH
MISSOURI/USA

1973
1973
1971
1973
1972
1970

If CASES
94

516
400
172
271
53
430
90
214
132
394
1653
548
1474
424
395
85
72
500
166
1052
199

944
230
965
228

261
1967
1975
1970
1968

1971
1974
1976
1976
1976

LAPPISH

1975
1975
1966

FINNISH
S. AFR . BANTUS
FRENCH
SPANISH
ISLAND
FINNISH

1971
1972
1973
1969
1972

2830

5237
262

378
39
186
26
68
187
504
219
330

1380
196
127
1000
2285
770
223
226
1520
576
450
1037
32)078

}1M

75.53
78.68
92.50
82.55
80.44
92.45
99.06
98.89
97.08
93.96
81.10
82.39
93.20
91 .. 66
97.64
96.96
96.47
91.67
88 .. 40
95.18
95.20
99.00
96 .. 03
89.13
96.80
95.80
91.20
89.75
88 .. 65
93.51
75.40
71 .. 79
93.01
88.46
100.00
97 .. 33
92.86
86.30
76.60
87.91
97.85
90.95
87.80
90.24
98.83
99.11
92.92
84.27
76.21
99.11
97.20

MS
2.13
3.29
0.50
1.74
2.58

-----

FM

MZ

20.21

14.34

0.58

2.50
9.88
10.33
3.77

1.75
0.58
2.21
1.89
0.69

-----

----~

0.30

1.80

12.70
11.19
3.50
2.85
0.23

1.52
0.12
0.40
0.28
0.23

----~

~----

----- -----

----- -----

----- --------- ----6.00

1... 22

3.30
0.50
3.21
6.96
0.50
O.llO

3.10
4.09

7.65
4.58
18.78
29.20
5 .. 38
11.53

-----

2.14
5.15
8.22
16.60
8.01
1 .. 61
8 . 27
7.30
6 .. 43
0.39
0.89
0.44
12.23
22 .. 74
0.89
' 0.77

1.00

........

-~

3.60
2.60
2.70
2.24
1.18
2.02
3.53
8.33
3.60

.....

0.30

0.50

1.18
1.30
2.50
3.80
4.50
2.54
0.61

0.21
0.411

-----

2.86

0.53

1.74
1.91
1.85

-----

1.07

-----

-----

----~----

0.53
0.60

0.20

----- 2.74
----- 3.00
0.22

-----

2.46

-----

0 .. 30
0 .. 44

--------6.64
0.19

3.50
2.19
0.78

-----

0.65
1.04

0.19

1.26

-----

GM

DM

EM

z-

LM

PZ

sx

c

E-

ES

MN

0.07

0.07

0.14

2.85

MQ

NN

YZ

5.30
0.25
0.06
0.20

0.12

0.06

0.82

0.44

0.07

0.07

0.07
0.54
0.10

0.13

0.06

1M
0.19
1.25
0.58
0.73

FF

MV

SZ

FS

IS

ZZ

FZ

MX

MW

MP

0.25

0.25

M-

LP

1.06

1 .. 06
1 .. 35
1.74
1.11
1 . 89

SS

0 .. 25
0.58

0.58
0.36

0.97

0.58
0.75

0.58
1.11

1 . 16

1.11
0.23
1.10

~-

............

0.70
0.76
0.25
0.66

0.30

0.20

0.48

0.25
0.24

0.27

0.07

0.25
1 . 39

0.25
0.12

0.06
0.07

0.07

0.18
1.09

0.07
0.76

0.20

0.20
0.60
0.20
0.50
0.32

0.11

0.10

0.10
0.87

0.87
0.10

0.40
0.04
0.02

0.40

0.10
0.21

0.40
0.04

0.20

0.07
0.10

0.14
0.23

0 . 14
0.34

0.53

0.53

0.08

0.91
0.60
0 .. 36

0.20
0.91
2.70
0.07

0.04

0.07
0.04

0.02

0.02

0.53

0.54

0.20

0.40

0.45
0.43

0.20
0.45

0.20
0.30

0.15
0.79

0.60
0.22

0.22

0.40
0.13

0.13

0.06

0.06

0.32

1.57

0.29

0.10

0.06

0.06

0.06

0.19

0.19

0.07

0.07

TABLE 10.

REF.

Pi ALLELES IN THE LITERATURE

ETHNY

M

s

z

F

OTHER

-

EUROPE
103
104
129
105
104
97
117
106
113
124
127
107
108
109
118
128
121
122
106
120
106
110

ileA

NORWAY
FINLAND
FINLAND
FINLAND
LAPLAND
ISLAND
DUTCH
GERMANY
GERMANY
GERMANY
IRELAND
FRANCE
FRANCE
FRANCE
FRANCE
SPAIN
SPAIN
PORTUGAL
PORTUGAL
GREECE
GREECE
IRAN
CAUCASIANS

94.63
99.55
98.55
96.62
99.42
99.56
95.58
96.70
87.89
97.34
93.65
91.08

2.30

1.33

-----

----

0.48
1.73
0.19
0.44
1.60
2 . 30
2.13
1.90
3.85
7.89

0.10
0.18

1 .. 57
0.45
0.67
1.37
0.39

0.17

283

---0.20

22
103

----

54
77
45
147
26
51
105
100
152

----

----

----.
-_ .... -

0.18

1.20
0.95
0.87
0.33
2.00
0.59

1.44
---0.10
0.14
0.35
0.18

2.20
1.42
1.19
0.74
2.28
1.82
1.62
0.30
2.21
0.92

0.21
0.90
0.62

----

9.01
0.19
0.15
0.13

90.10
90.19
86.64
97.94
92.00
86.51
95.87
96.00
88.38
93.78

6.60
7.13
11.24
11.50
5.48
11.52
0.25
2.80
2.21
4.30

0.89
0.36
0.26

96.46
98.18
96.97
98.34

0.22
1.64
----0.12

3.32
0.18

----

----------

0.12

0 .. 59

98.30
97.90
98.35
99.42

0.30
0.20

1.40
1.90

--------

----

1.01
0.58

0.63

----

94.83
98.04
95.20
93.80
93.70
98.93

3.60
0.98
1.70
3.20
4.31
0 . 81

1.16
0.49

-------

2.90
0.50
0.11

----

----

----

0.20
0.70
0.47
0.27

99.25

0.75

----

----

----

----------

1.25
0.60
6.82
0.32

39
165

----

37
57

0.23
0.15
1.01
0.30
0.37
0.68

21
33
40
50
27
523

------3.03
0.83

22
27
13

----

0.25

----

----

96
23
39
43

AFRICA
126'
106
107
110

S . AFR. BANTUS
NEGROES
BANTU
BLACK

42

ASIA
116

110
106

JAPAN
AINU
INDIAN
INDIAN

----

AMERICA
125

US MISSOURI(W)
(B)

116

u.s.

III

US NEW YORK
US CALIF (\-1)

123

(B)

-------

~

1.80
1.41

193
20
26
50
138

18

OCEANIA
114

NEW GUINEA

19

~OPULATION

if OF SUBJECTS

M

1867

82.81

12.80

WHITE

1024

87.10

8.48

BLACK

462

96.96

1.52

LYON, FRANCE

MS

FM

MZ

1M

2.36

0.65

2.53

0.68

PHENOTYPES
MV
SZ
S
0.05

0.16

0.70

0.09

0.19

IS

MX

0.05

MP

LM

PZ

SX

0.27

0.05

0.05

0.05

0.19

0.09

1.08

0.21

MN

N

:HARLESTON, SC

0.29

0.21

ALLELES
F

Z

OTHERS

M

S

90.81

7.23

1.29

0.60

WHITE

93.89

4.49

0.15 1.32

0.15

BLACK

98.80

0.75

CYON, FRANCE
iCHARLESTON, SC

~
~M

VARIANTS ARE LISTED AS M)

0.45

0.19

0.09

41

Frable 12

Serum APi concentrations (by radial ~unodiffusion)
according to phenotype
Phenotype

Mean va1ue*

S.D.

NO. tested

53.88
55.04

166

(mg%)

M

Me
Mb
rt~1c

MS

McS
MbS

MZ
~1cZ

MhZ
MP

McP
1M
IMc
1M
MV

S
SZ

IS
PZ
SX

235.48
250.53
250.24
237.11
203.33
218.98
214.11

147.17
132.50
145.00
123.67
'135.00
186.00
189.25
248.00
210.00
158.54
123.33
149.00
70.00
197.00

48.17
57.23

64
34

81

42.50
54.09

84

47.12

19

33.14
14.37
----16.61
19.80
50.14
46.91

30

-----

51
8

1

3
2
8
4
1

---~-

1

35.97

13

9.60
--- ............
-----

3
1

-_...- ....

1

1

*Expected values vs. M (% of e~ression of the M allele) are for
M 100%, l'-lc 112.8%, Mb 112.5%, S 72.08%, Z 24.99%, and I 53.96%.
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with infantile cirrhosis, are clearly higher than those calculated from
asymptomatic Z subjects. This can be attributed to the fact that APi
appears to be an acute-phase reactant protein although APi levels do not
appear to become elevated in response to stimuli such as estrogen
treatment or typhoid vaccine (132,133). Thus, these results could
explain the observation that APi levels in several patients in our study
who presented with either liver involvement or chronic obstructive
pulmona~ disease were higher than expected in association with the Z
allele. A review of the Z pi values associated with liver disease in
recent reports (134-138) confirns this finding.
Serum APi values are also decreased in association with 1M
phenotypes (Table 12). Family studies grouping 38 cases of I
heterozygous phenotypes confirmed these results (Table 13). The
rnicroheterogeneity of the I allele is unusual in that band 6 is
considerably weaker than that observed with most other allele products
(139). In addition, our studies clearly demonstrate the existence of
two variants of Pi I -- II (85%) and I2 (15%) -- based on a slight
difference in the isoelectric point of all bands, a situation similar to
that existing with respect to M and Me (Fig. 9). Both I variants are
associated with a mean reduction in serum APi levels of 16%, a figure
which is very s~ilar to that found for the S alleles in MS phenotypes.
The reason for the decreased serum APi levels is at present not clear,
although it is interesting to speculate that it may be an example of
deficiency due to a decreased amount of one individual component of the
rnicroheterogeneity, in this case 16.
IV.

Distribution of Pi

Phenot~s

in Cord Blood

we undertook a study of pi phenotypes in cord blood for several
reasons;
1. A newborn population represents a random sample of a population
for which no selection is applied to the subjects with respect to
criteria of health (blood donors, students) or disease (patients with
lung or liver involvement).
2. ~he association of pi variant phenotypes with an increasing
number of pathological conditions, and the possibility of preventing
their appearance or mdnimizing the consequences by preventive measures
might represent a strong argument for performing systematic pi typing at
birth.
3. The easy access to cord blood at birth, the ability to obtain a
simultaneous blood sample from the mother, and the availability of at
least part of the family at this time greatly facilitate Pi typing and
family studies.
14,

The results of this
suggest that

prel~inary

investigation, indicated in Table

1. pi phenotypes can be readily recognized in cora blood (140).
All the variants found have been confirmed on fresh blood samples
obtained from the babies between I week and 1 month after birth. The Pi
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Table 13
Cornpar ison of sertun APi values for IM and H
phenotypes (by radial ~unodiffusion)

No. of cases

Mean value*

S.D.

(rng%)

IM

38

198.11

42.13

M

166

235.48

53.88

*Significance for difference between TIM and M, P < 0.001.
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Table 14

Distribution of Pi phenotypes of APi in newborns (cord blood) and in mothers
No.

M

MMc

Me

~1weak*

MS

Newborns

225

171

24

4

5

15

Mothers

225

171

20

5

17

MeS

MZ

McZ

PM

3
3

2

IM

IM

1

2·

1

1

3

MV

1

1

*Mweak is an M variant characterized on isoelectric focusing by the presence of M bands in the
norrral position, but especially weak. It is associated with low values of serum APi measured by
radial ~unodiffusion. It seems to correspond, in the newborn, to a temporary defect in APi
secretion. New samples obtained in four cases in this study, one month after birth, showed
normal radial ~unodiffusion values and a normal Pi type.

~
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variant phenotypes of the' babies were also found in the mother in 48% of
the cases.
2. The ~croheterogeneity of the pi allele products is somewhat
different from that of pi phenotypes in adults. In all phenotypes
observed, there was a relative decrease in intensity of bands 4 and 7,
and a relative increase in bands 6 and 8, clearly illustrated by crossed
~unoelectrophoresis (Figure 10).
These changes disappear
progressively and the adult pattern is established in babies within one
~nlli.

3. In approximately 48% of the cord samples, additional bands can
be observed (Fig. 11). They do not seem to be artifacts, for they
persist after treatment with B-mercaptoethanol and they do not resenble
the patterns due to serum alteration (141). Tney do not represent APi
of different molecular weight since they are still present in the 50,000
dalton peak after gel filtration on Sephadex G-200. In addition, they
appear to be identical to bands of APi extracted from placental tissues
(142). The additional bands decrease in intensity and disappear within
a few days following birth. These finding suggest tl1at placenta may
contribute to APi present in cord blood by the production of molecular
species that differ from those synthesized by the liver in adults. The
different distribution of APi bands in cord blood has already been
reported for the MM phenotype (143-145). It had been proposed that this
phenomenon could be due to an insufficient sialylation of band 4 (143);
however, during experiments involving enzymatic desialylation of APi
with neuraminidase (Chapter 4), we have shown that the removal of only
one sialic acid moiety causes a shift in isoelectric point of
approximately 0.1 pH units (146), which would be readily observed in the
thin-layer isoelectric focusing technique. Since there was no
demonstrable shift in migration of M4 and M6, this explanation seems
unlikely; and more recently we have found the same pattern in an adult
serum (105)~ we propose that the basis of this fetal pattern is an
altered secretion of the molecular variants that constitute the
microheterogeneity. According to the hypothesis whereby synthesis of
each band of APi microheterogeneity is accomplished by a single clone,
this deficiency would express brunaturity of the corresponding clone at
birth. S1milar examples have been clearly documented for TImmunoglobulin
G and hemoglobin molecules (147) in the newborn.

v.

Conclusion

A. The pi System as a Genetic Marker: Following the recent
discovery of new and M variant alleles, the pi system has evolved into a
very useful genetic marker. At a practical level, pi typing is
inexpensive, and unlike many other genetic polymorphisms a permanent
record of Pi types can be kept. More than 25 different alleles have
been described, of which the most common is present in only 50% of
Caucasian populations, and the number of theoretical combinations
exceeds 400. Evidence suggesting linkage with Om markers further
enhances its interest.
B. Necessity for extensive systematic population studies of Pi
phenotypes: ~he significance of the association of pi variant
phenotypes with various disorders is valid only when comparison is made
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Fig. 10.

Comparison of crossed ~unoelectrophoresis of an adult M
(top) and a fetal H (bottom) pi phenotype. Note the decrease
in band M4 in the fetal sample. First dimension, anode at
the left; second dirrension, anode at the top.
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Fig. 11.

Comparison of two~ fetal f.'l patterns of APi (left) \vith t\vO
adult H patterns (right) on isoelectric focusing. Note the
presence of two additional bands in the fetal patterns, one
between H4 and N6 and the other more anodal than 1>14- Also
note the relative weakness of t-14 and t17 in th2 fetal
patterns. Anode at the top.
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with reference populations derived from the same geographic area, the
same ethnic origin, and phenotyped with the same method.

c.

pi type determination in newborns: The firm association of
deficient pi types with pulmonary and liver disease and the convincing
evidence of the increased prevalence in several disorders of connective
tissue (see Chapter 4) could argue in favor of systematic pi type
deteLmination at birth. The discovery of deficient phenotypes could
have immediate consequences in genetic counseling and preventive
actions. The suggestion of possible substitutive therapy either using
normal APi (148) or synthetic analogues (149) may be justified in view
of the relatively high risk of deficient individuals developing these
diseases (see Chapter 4).
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Chapter 3
STRuc'rURE AND BIOLCGICAL ROLE OF APi

I.

Biochemical Characteristics

APi has been characterized in several biological fluids, including
cerebrospinal fluid (150), tears (151), arrniotic fluid (152), pleural
and peritoneal exudates (153), cervical and selninal fluids (154), and
duodenal fluid (155). But its principal location is the extracellular
fluids: 40% of APi is present in serum (156) at a concentration of
2 ug/ml, and 60% is in the extravascular compartment. Alpha-2
macroglobulin, the second protease inhibitor in importance, is mainly
(80%) present in the intravascular compartment (156). Thus, the
predonunant role of APi in the extravascular space is obvious.
APi synthesis appears to be alrrost exclusively located in the liver
(157). Its accumulation inside the hepatocyte can be shown when the Z
allele is present (158), and the presence of PAS-positive granules has
largely been demonstrated in this case both py conventional (159) and
electron microscopy (160) techniques. These granules are located in the
rough endoplasmic reticulum (160) and can easily be differentiated from
glycogen, for they are not modified after diastase digestion (161).
They are round or ovoid globules of diameter between 0.5 and 40 urn.
rrhey could be confused with 1ipofuchsin deposits (162). In addition,
they react specifically with an immunofluorescent or iromunoperoxidaselabeled specific antiserum against APi, proving that this material is
antigenically similar to APi (163). (Further information on APi
retention inside the liver cell can be found in refs. 164 and 165.)

In addition, in two cases of liver graft for cirrhosis of the liver
with APi deficiency associated with ZZ phenotypes, the phenotype of the
donor replaced that of ti1e recipient soon the graft, further
demonstrating the hepatic origin of serum APi (166,167).
In addition to its presence in liver cells in the case of Z
phenotypes, APi can be shown in normal subjects in rnacrophages (168) and
in platelets (169). ~vo studies have demonstrated the presence of
granules containing an APi-related material in yolk-sac tumors (170,171)
and in the metastasis of a hepatoma in a patient with ZZ phenotype
(172) . 'rhe s ignif icance of the presence of APi-secreting cells othe r
than hepatocytes will need further investigation.
rI'he half-life of serum APi has been estimated by Hakino (173), who
injected radiolabeled asialo-APi in huroan volunteers, to be 6 days.

Talamo (174) injected nor~al APi in a subject with complete APi
deficiency (Pi null) and found similar values. Recently, Miller (180)
studied the half-life of hurnan l\Pi injected in rabbits: Nand Z APi
variants had approxirret.ely the sarre half-life (10 hr), whereas
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asialo~APi

had a half-life of only 6 min, and the half-life of the
APi-trypsin complex was estimated at 1.5 hr. The discrepancy between
these results and those of Makino (173) will also need further
investigation.
Isolation and purification of APi have been reported py several
authors (175-191). The techniques of purification were usually a
combination of salt fractionation, ion exchange chromatography, and gel
filtration (176), or more recently, were based upon affinity
chronatography (183). We report here (Table 15) a new three-step
technique that provides a pure material suitable for structural studies
of the corrponents of the microheterogeneity •. Another technique,
involving concanavalin A purification of APi as a first step, is also in
progress in our laboratory.
The amino acid corrpositions and rrolecular weights of APi, as
reported py several authors, are indicated in Table 16. There is good
overall agreement between the different results, but individual
variatio~s can be noted.
1he majority of the authors agree on the
presence of two cysteinyl residues in the APi molecule, forming a
disulfide bridge. Thus., the secondary structure of APi would corrpose a
loop.

'l°he problenl of the sugar chains of APi is rrore controversial. A
summary of the proposed composition of the sugars of APi is given in
Table 17. There exist important differences, especially for the sialic
acid content, which varies from 2 to 10 residues, with an average
content of 7 residues. Recently, Chan (186) reported in a
well-documented stuqy the linear structure of the oligosaccharide chain
of APi (Table 18). If this structure is confirmed, it would tend to
indicate that the results of the majority of other authors are
consistent with those of Chan, except for the lack of one sugar chain.
Preliminary results in our- laboratory·indicate that one sugar chain of
APi type M is labile and can easily be removed during purification
steps, especially those involving gel filtration.
In Tables 16 and 17, the amino acid and sugar compositions obtained
from published data are compared for the M and the Z variants. No
striking difference appears in the amino acid composition, at least when
the different reports are compared (Table 19). Chan (177) reported that
serum Z protein lacked one of the four sugar chains present in the M
protein. Following this suggestion, it was proposed that the Z molecule
lacks one arrdno acid able to bind a sugar chain, i.e., asparagine,
serine, or threonine. The comparison of the amino acid composition of
the M and Z proteins does not favor this possibility. A recent report
(182) studying the results of peptide mapping of tryptic digests of M
and Z variants indicated that the latter presents a single amino acid
mutation, lysine instead of glutamic acid. Similarly, Owen (192) and
Yoshida (193), studying the differences in peptide map between Pi M and
the S variant, demonstrated the presence of a single amino acid mutation
(valine in S instead of glutamic acid in Ivl). Thus, in the Z as in the S
variant, a glutamic acid of the r.1 protein appears to be replaced by
another amino acid. The basis of the polymorphism of APi variants would
then be explained on the basis of single amino acid mutations possibly
affecting the same amino acid (glutamic acid) of the M molecule. Its
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Table 15

APi Purification
Starting material:
'Step 1.

20 ml serum

Removal of albumin

Gel filtration on

Ci~cron

blue Sepharose

Total protein applied on the column: 1200 rng
Total APi applied on the column: 40 rug (APi:protein = 3.33%)
Total protein recovered: 540 rng
Total APi recovered: 36 mg (APi:protein
Purification:
Step 2.

= 6.66%)

50%

Isolation

Preparative flat bed isoelectric focusing in a pH gradient 3.5-5.5
(supporting medium: Sephadex G75 Ultroaex)
Total protein applied on the gel: 540 rng
Total APi applied on the gel: 36 rug (APi:protein

= 6.66%)

Total protein recovered in the selected zone: 30 mg
Total APi recovered in the selected zone: 25 mg (APi:protein
Purification:
Step 3.

~

83.33%)

76.7%

Subtractive affinity chromato9raphy

An antiserum against pi null is obtained in rabbits ~ immunization with
human serum totally deficient in APi. The globulins are obtained by
DEAE-ce1lulose chromatography. They are linked to 6-arrdno hexyl Sepharose.
This column binds all the serlli~ proteins except APi.
Total protein applied on the colurrn: 30 rng
Total APi applied on the column: 25 rug (APi:protein = 83.33%)
Total protein recovered: 21 mg
Total APi recovered: 21 mg (APi:protein = 100%)

Table 16

Amino acid corrposition and rolecular wei9ht (M.W.) of nomal (M.'It\) and deficient (ZZ) APi proteins
~

Ref.

no.

~no acid co~ition (residues/mol)
________________________________________________
----__________________________ "

Ala

Ar9

Asp

Cys

Clu

Gly

His

Ile

Leu

Lys

Met

Phe

Pro

Ser

'n1r

Tep

'l'yr:

Val

H ~W.

K fhenotYel

175

23

9

40

2

45

22

12

18

50

35

8

2,

23

22

30

4

7

25

55,000

176

24

7

44

1

59

22

13

18

45

32

8

29

16

22

"31

2

1

23

50,30&

117

27

8

43

54

.22

12

18

44

37

9

28

19

27

33

6

24

54!00B

178

26

7.7

44.1

2

52.4

25.9

14.0

18.9

48.5

36.5

8

29.9

18.1

21.1

30

2

6.8

26.5

56,009

119

26

1

46

2

55

24

12

17

44

36

8

28

IB

21

30

2

7

23

50,50B

180

22.1

6.8

40.8

1.8

47.1

20.8

11.8

16.3

42.4

36.9

1.6

23.9

17.7

19.7

25.6

3.1

5~2

22.2

41,00B

181

22

7

40

S.4

46

21

13

17

41

32

6

26

16

20

28

3

6

24

52,000

182

24

6

40

2

S3

21

11

16

52

30

9

28

25.

22

29

2

6

21

53(El00

183

23

6

42

1

51

24

13

17

46

32

10

26

16

18

26

2

5

24

42,400

184

25

7

47

4

55

23

13

20

48

41

6

27

23

23

26

1

6

25

53,000

18S

22

6

38

8

46

19

12

16

39

30

7

23

15

18

26

2

6

21

54,000

186

24

.8

44

2

52

23

12

21

S1

36

8

29

19

21

28

3

6

27

51,009

la1

26

10

40

2

53

22

12

16

41

33

9

26

18

23

28

2

8

22

S4,009

las

26.6

7.5

44.8

23.7

12.5

20.6

45.0

35.1

7.5

2B.2

18.3

22.5

28.5

1.8

6.9

26.8

50,009

12

42

51'

30

13

16

33

9

26

19

27

29

54.1

30.3

14.7

20.0

41.7

37.3

20.8

19~2

23.9

21.6

..

1.7 . 59.2

Z ph eno~

177

27

178* 29.6

14.2 . 40.9

180

22.8

7.1

41.1

1.7

45.3

19.6

12.0

15.9

42.7

38.2

7.6

23.9

19.2

20.6

27 .. 6

182

26.3

S.9

41.S

2.4

53.9

21.7

10.5

15.6

51.7

30.9

8.2

27.2

25.9

22.8

26.4

188

25.7

7.5

42.8

l.7

50.0

32.2

13.4

20.2

44.4

33.B

7.2

28.1

18.8

21.9

28.1

24

8.2
3.1

27.4

5.6

23.8

2.1

6.1

21.2

1.9

6.2

26.5

, *lsolated from the liver.

.

.
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Table 17

Sugar composition of alpha-I-protease inhibitor
Ref.
no.

No. of residues
N-acety1g1ucosamine

Sialic
acid

Hexoses

'rotal

D-mannose

D-galactose

Serum M protein
175
176
177
178
179
189
190
180
191
181
182
184
185
186
188

9

10
13
12
10
14
12
11.6
16
9

13
17
10
14
13.6

14
12
21
16
17
22

18
13.5

5

9

7
12

5

6
6

8

9
8

6.5

10
12

7
10

9

9

6.3

5.2

9
7

10
6.5
7.6

22

15
17
21
14
20
19.7

6

7
2
6
9

5.9

Serum Z protein
177
190
180
191
182
188

11
12
10.9
9

13.9
13.6

14
18
7.9
18
16.5
22.4

8
9

6
9

4.6

3.3

5

5.2
5.6
1

5.2
6.4

Liver Z protein
178
190

1.5
1.5

5.1
5.3

3.6
3.6

1.5
1.7

0

'-1

Table 18
Pc imary structure of the t\vO sugar chains of APi

(modified from Chan et al., ref. 177)
~1

Chain A
SA*- G.l\L -

NAGA -

(HAN) 3

-

(NAGA) 2

-

ASN

Gk

I

SA
,

"

Chain B
SA

I

~
SA-

GAL"- NAG1\ -

(t1AN) 3 -

(NAGA) 2

~

ASN

NlGA

~
I

...-Protein chain

SA

#a:3A, sialic acid; NAGA,

ASN, asparagine.

l~-acetylglucosaminei

r·lAN, rrannose; GAL, galactose;

Table 19

Differences in amino acid corrposition between H and Z APi proteins

APi

Amino acid conposition (residues/lTOl)

type
Ala

27
K
S
27
2-ii*

M9

Asp

8

43
42

12
+4

-1

26
29.6
+l.6

7.1
14'.2
+6.5

40.9
-3.2

ZooM

22.7
22.8
te.l

6.8
7.1
+0.3

40.8
41.1
+0.3

"

26.3
+2.3

-0.1

+1.5

+2.615 -8.6

K
.Z

Zwtl
K
Z

Z
%-K

24

6
5.9

44.1

Cys

2.0

1.8
1.7

-0.1

2
40
41.49 2.31
+1.5 +0.4

Glu

Gly

His

Ile

Leu

Lys

Met

Phe

Pro

Ser

'!br

54
51
-3

22
30

12

18

44

+1

-4

28
26
-2

19
19

+8

43
-1

9
9

33

16
-2

31
33

27

13

29.9
20.8
-9.1

18.1
19.2
+1.1

21.7
23.9
+1.2

27.6
-2.4

6.8
8.2
+1.4

26.5
21.4
+0.9

23.9
23.9

17.7
19.2
+1.5

19.7
2a.6
+0.9

25.6
27.6
+2.0

3.1 - 5.2
3.1
5.6

22.2

14.0

52.3 25.9
54.1 30.3
+1.7 +4.4

+0.7

18.9
20.0
-1.1

48.5
41.7
-6.8

36.5
31.3
+0.8

8

14.7

41.1 20.8
45.3 19.6
-1.8 -1.2

11.8
12.0
+0.2

16.3
15.9
-0.4

42.4
42.7
+0.3

36.0
38.2
+2.2

7.6
7.6

28
16
52
30
9
53
11
21
53.85 21.76 10.49 15.54 51.67 30.90 8.16 27.1
+0.9 +0.7 -0.5 -0.4 -0.3 +0 .. 9 -0.8 -0.8

27

22
25
25.85 22.8
+0.9 +0.8

29

-4
JCJ

)

, difference ootwe-en the two types.

+2.975 -

-1.95

-

2

Tyr

Val

6
6

24
24

+0.4

2).0
+0.8

2
29
6
21
28.43 2.13 6.09 21.21
-0.5 +0.1 +0.1 +0.2

lege
!ere~

"rrp

-2.975 +0.875 +0.725 --
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translation of the whole pattern toward the anode or the cathode. Such
results, which will need further confirrration, especially bj the
determination of the conplete aITtino acid sequence of each variant,
confirm our theory of the basis of the polymorphism, proposed two years
ago (194), which is similar to the theoretical basis of the polymorphism
of llnmunoglobulin markers responsible for the existence of the Gro
system.
reports (83,210) have established the partial N-terrrdnal arrdno
acid sequence of the first residues of APi ·type M. This sequence is
indicated in 'l'able 20. Similarly, Chan (personal comrrunication, 1977)
has delineated the sequence of a major glycopeptide comprising 120 amino
acids and obtained by cleavage of the APi rrolecules bj cyanogen bromide.
~wo

The basis of the microheterogeneity inside an allele product is
also controversial. Crawford (176) reported that a complete
desialylation of pure APi did not modify the microheterogeneity of APi
but resulted in a shift of the whole pattern toward the cathode.
Partial or complete desialylation of serum APi (195-197) gave
contradictory results. Laurell (190) recently reported that the
rrdcroheterogeneity could result from different degrees of sialylation of
the same molecule. In contrast, Talamo (199) suggested that after
desialylation, serum APi still remained microheterogeneous.
In an attempt to clarify these discrepancies, we performed a series
of desialylations of crude serum. APi variants M and Z were separated
before and after desialylation b¥ isoelectric focusing in a pH gradient
3.5 - 8.0 and studied by print immunofixation. Microdensitometry of the
prints was also perforrred. ~he protocol of the experiment is indicated
in Table 21 and the results obtained are shown in Figure 12. Complete
desialylation was assumed when no additional sialic acid could be
detected py the Warren technique after hydrolysis in 1 M Hel at 8eOc for
2 hr. Comparison of the migration patterns of the different phenotypes
before and after complete desialylation (Fig. 12) shows the following:

1) Microheterogeneity of APi remains identical before and after
desialylation. This fact indicates that sialic acid does not account
for APi microheterogeneity nor for the t-'1 variant or Z variant.
2) The respective positions of M and Z
desialylation are identical. This suggests
acid for M and Z proteins is identical, and
possibility of a rrrrssing sugar chain in the

variants before and after
that the content of sialic
thus does not confirm the
Z protein.

3) The shift in isoelectric point for each band is identical and
corresponds to 1.0 pH unit (+ 0.05 units). As each sialic acid
contributes to the net charge of a molecule for 0.1 acidic pH unit, this
result indicates that each APi molecule contains 10 sialic acid
residues. This result is in complete agreement with ti1e recent results
of Chan (189). ~he discrepancy between the results presented here and
some early reports on this subject can c€ explained b¥ technical
differences; i.e., desialylation cQula have been incomplete, and in
addition, analysis of asialo-APi was done using acid starch gel and
crossed iIT~noelectrophoresis, both techniques having less resolving
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Table 20

Partial N-terrninal amino acid sequence of alpha-I-protease inhibitor
1234567
NH2-

8

GLU

ASP

PRO

GLN

GLY

ASX

ALA

ALA

1

2

3

4

5

6

7

8

9

10

ASP

PRO

GLU

GLY

ASP

ALA.

N..A

GLU

ASP

NH2- GLU

(I)

*(1) From Musiani (ref. 183); (2) From Johnson (ref. 210).

(2)

*
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Table 21
Desialylation of APi
1.

pH adjustment of serum

1.0 rnl of serum is dialyzed overnight against
acetate buffer 0.1 M, pH 5.0.
2.

Neuraminidase treatment

100 ul of serum is added to 200 ul of neurarrdnidase
(EC 3.2.1.18) containing 500 units/ml ~ehringwerke).
The mixture is incubated at 37OC.
3.

Analysis of the effects of neuraminidase
Aliquots are taken at different times. They are compared
with untreated serum using isoelectric focusing (pH
3.5-8) followed ~ print immunofixation.

4.

Sialic acid measurement

Total CHP digestion of serum protein is carried out in
Hel 0.1 N at 80°C for 1 hr. The release of sialic acid
is measured using the Warren thiobarbituric assay
(analysis kindly perforrred by Dr. G.B. Wilson, Departrrent

of Basic and Clinical Immunology and Microbiology, MUSe).
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Fig. 12A.

3+-~~~~~~~~~

abc

B

d

o

23456789

em from Anode
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{A} Serum APi desialylation. a, native Z APi; h, asialo Z
APi; c, asialo H APi; at native M APi. (8) a, native H APi;
band c, partially desialylated H APi; d, asialo M APi. (C)
pH gradient in the gel related to the distance from the
anode. pH gradient: 3 .. 5-8. Anode at the top. The patterns
for APi \.;rere obtained bj print immunofixation of serum.
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Fig. 12B.

Print irnrrunofixation of native (top) and asialo (bottom) r'1
Anode at the top. pH gradient: 3.5-8.

and Z APi.
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power than isoelectric focusing and print immunofixation, especially in
this zone of pH.

In summa~, the differences in the polymorphism between the M and Z
molecules do not lie in sialic acid differences. Amino acid mutations,
as the one reported py Yoshida (182,193), could be, as discussed above,
responsible for the translation of the whole pattern. Preliminary
experiments indicate that the S molecule after desialylation behaves
identically to the asialo,~ and Z when compared with the intact
molecule. All these facts are in favor of different amino acid
substitutions in the sarre region of the molecule responsible for the
basis of the polyrrDrphism (194).
Similarly, the microheterogeneity cannot be explained on the basis
of sialic acid differences. Although differences in other sugars could
be involved in the origin of the multibanding pattern, this hypothesis.
seems unlikely. It would be logical to propose that each band that
constitutes the ~croheterogeneity also differs ~ single amino acid
mutations. These bands could correspond to the expression of different
genes at a single locus in each individual. They could also, in our
hypothesis (194), correspond to the product of different clones,
differentiated from an original cell qy somatic mutations, which would
be responsible for the production of each band inside the macroheterogeneity of an allele product.

II.

Biological Role of APi
As reported above, APi represents the najor protease inhibitor of

extracellular fluids. It is known to inhibit a wide variety of
proteases (Table 22). In normal circumstances, the major role of APi as
antienzyme is mainly concerned with elastase and collagenase released
from granulocytes, and with proteases of microbial origin. A role of
APi in preventing an uncontrolled activation and inactivation of the
coagulation mechanisms has also been recently suggested (156). The
interaction of APi with proteases is therefore of major interest and is
concerned with processes as vital as inflammation, infection, and wound
healing (200).
The interaction between APi and both trypsin and elastase has been
extensively studied, mainly py Ohlsson (201-209). We here present the
results of our studies on the interaction between APi and these two
proteolytic enzymes.
protocol of the e~eriments is indicated in Table 23 and the
results are shawn in Figures 13 and 14. They deserve the following
corrurents:
~he

1) In excess of APi, a complex between APi and proteases is formed.
This complex is stable at room temperature for at least 24 hr. The
amount of complex formed is proportional to the quantity of protease
added (Fig. 13A).

2) In excess of proteases, the complex between APi and proteases
progressively disappears. It is replaced qy another pattern that is
much rrore acidic but slightly less so than the intact molecule (PI).

Table 22

Specificity of human plasma inhibitors
Inhibitor

Enzyme inhibition
Trypsin Chyme- Plasmin
trypsin

Alpha-I-antitrypsin

+

Alpha-l-antichymot~sin

+

PlasmaKallikrein

PancreasKallikrein

+

+

+

?*

weak

?

Inter-alpha-trypsin inhibitor

+

Antithrombin III

+

Cl inactivator

weak

weak

+

+

Alpha-2-rnacroglobulin

+

+

+

+

Thrombin

ClEsterase

+

Elastase

+

+

weak

+

+

+

*?, not yet determined.

'"co
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Table 23

Binding of
1.

t~sin

and elastase to serum APi

Study of the farnation of the complex between APi and proteases
An identical volume of serum (100 ul) is incubated at room

temperature for 2 hr with increasing quantities of t~sin or
elastase. The ratio of proteases to APi varies from 1/1 to 1/64.
2.

Study of the formation of APi inactivated by proteases

100 ul of serum APi is incubated with proteases in a 1/2 molar
ratio. Samples are taken at dfferent intervals (10-60 mQn).

3.

Analysis of APi and

co~lexes

The samples are studied qy isoelectric focusing in a pH range 3.5-8
followed qy print immunofixation. The quantitation of the
different forms is made py microdensitometry of the immunoprints
(courtesy of Dr. R.C. Allen, Department of Pathology, MUSC).
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Fig. 13A.

.,-.

Interaction behleen serum APi and trypsin. Print
irnmunofixation of serum APi incubated with different arnounts
of trypsin. Note the increasing quantitites of complex
relative to the increasing amounts of t~sin added. The two
patterns on the right shoN the coexistence of degraded
product (PI) with the corrplex. Anode at the top.
pH gradient: 3.5-8.
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Fig . 138.

Interaction between serum APi and trypsin.

Detail of the

degradation product (PI) corrpared \'-lith native serum APi.
Note the presence of two additional cathodal patterns, \vhich

correspond respectively to P2 (rrore basic) and P3 (more
Print iwrounofixation. pH gradient: 3.5-8.
Anode at the top ..
acidic).
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Fig. 13B.

Interaction between serum APi and trypsin. Detail of the
degradation product (PI) corrpared with native serum APi.
Note the presence of two additional cathodal patterns, which
correspond respectively to P2 (rr.ore basic) and P3 (more
acidic). Print iwmunofixation. pH gradient: 3.5-8.
Anode at the top.
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•

Interaction behveen serum APi and trypsin. Kinetics of
dissociation of the complex and the appear&lce of degradation
products. rr'he relative proportions of corrplex and breakdalln
product are calct)lated from microdensitornetric tracings of
the irnmunoprint (courtesy of Dr. R.C. AlIenI Departrrent of
Pathology I HtJSC).

I

I

I
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Fig. 14.

.,

Interaction bet\veen serUi11 APi and elastase. rr'he results are
similar to those obtained ~ incubation ·with trypsin. Note
the differ"e nt isoelectric points of the corrplex and the
breakdaNn product when corrpared with ·those resulting from
incubation \vith trypsin. Anode at the top. pH graoient:
3.5-8.
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TWO other patterns can be seen in addition, one more basic (P2) and the

other more acidic (P3) than the complex (Fig. 13B). The formation of PI
is time-dependent, and in excess of protease all the complex is
converted to PI after 1 hr of incubation at 370C (Fig. l3C).

3) The microheterogeneity of APi rerrains identical within these
different patterns, indicating that these different steps identically
affect each component of the APi rnicroheterogeneity.
4) rr'he isoelectric point of the complex and of the different
patterns is different for trypsin and for elastase (Fig. 14).

Our interpretation of the results is as follows:
1) wnen the ratio of APi to enzymes is in favor of APi, a stable
complex is formed. The protease is trapped inside this complex and
loses all proteolytic activity.
2) In excess of proteases, APi is saturated. 'l'he conplex is then
attacked by free partial proteases. The molecule of APi undergoes a
proteolytic cleavage and gives a degraded product (PI). The modified
APi, due either to the rerooval of an essential "trapping fragrrent" or to
a modification of its quaternary structure, can no longer inhibit the
protease, and the complex is dissociated. The altered product is then
liberated ana the rrodification in charge in its primary structure due to
the removal of the fragrrent is indicated by the change in its
isoelectric point.
'rhe patterns P2 and P3 could correspond respectively to the conplex
of intact APi with two molecules of proteases, and to the complex
between protease and degraded APi before release of the protease
(F'ig. l3B).
~he

summary of this interpretation is indicated in Table 24.

The difference between the isoelectric points of degraded APi after
proteolysis py trypsin and elastase tends to indicate that the points of
cleavage of these two enzymes on the APi molecule are slightly
different.
These results agree with the observation ~ Johnson and Travis
(210) that the dissociation of the complex between APi and t~sin
liberates an APi rrolecule whose rrolecular weight is 8000 units lCMer
than the intact molecule.' This molecule, in addition, has lost its
inhibitory capacity. Similarly, Lo (18?) reported that the interaction
of APi with elastase gives two complexes of 73,800 and 58,300 daltons
and fragments that do not inhibit enzymes, but retain immunological
characteristics of APi.

'lbe dose-dependent interrelatonship between proteases and APi has,
to our knowledge, not hitherto been reported. This finding is striking,
for it indicates that this interrelationship is based not on the
absolute level of proteases or their inhibitors but on the ratio between
this level. There is, at least in vitro, a "safety" level at which
proteases are steadily inactivated and a "hazard 1t level at which the
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Table 24

Interpretation of the results obtained from binding of proteases with APi

1.

In excess of APi
APi + protease - ) APi-protease (stable at 22°C for 24 hr) + free APi

2.

In excess of protease

APi + protease ---> APi-protease + free protease
APi-protease + protease ---) protease-APi-protease (pattern 1)
protease-APi-protease

---> protease-APi* (pattern 2)

protease-APi* ---) APi* + protease

APi*, altered APi.
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capacity of inhibition is overcome and inhibition disappears. At this
ratio, which even CQuld be the normal level of APi if the level of
proteases is higher, the inhibiting capacity is inefficient. 'I'his
"critical" level of inhibition could explain why in vivo there is no
progressive effect of proteolytic enzymes. In fact, individuals with
severe deficiency (ZZ) suffer from clinical disorders in the great
majority of the cases, whereas heterozygous patients seem to be free
from any disorder induced ~ proteases (see Chapter 4). Similarly,
under certain acute circumstances, an excessive liberation of proteases
could temporarily, by increasing one of the factors, produce a dramatic
excess of proteolysis in individuals protected under normal
circumstances. This would introduce a new pathogenesis, which would
incluae not only the level of protease inhibitors but also the
protease~antiprotease

ratio.

The structural variation of APi, due both to its rrdcroheterogeneity
and its polyrrorphism, the association of decreased serum values with
certain phenotypes of this protein, and the mechanism of inhibition of
proteases clearly indicate the need for additional structural and
kinetic studies on this rrajor protease inhibitor.
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Chapter 4
APi DEFICIENCY AND DISEASES

The association of APi deficiency with clinical disease has given
new impetus to the study of this protein. In addition to the discovery
of high frequencies of pi deficient phenotypes and their possible
relevance in pathophysiology of several disorders, these observations
have stimulated research designed to explore the biological consequences
of APi deficiency.

I.

Pulmonary Diseases

In the first report on the association of pulmonary emphysema and
APi deficiency, Eriksson (211) indicated that the incidence of chronic
obstructive bronchopulmonary (COPD) disease was 15 times higher in
IIhomozygous deficient" subjects than in normal populations. He reported
also that relatives with heterozygous deficiency did not present an
increased evidence of COPD. Soon afterwards, Fagerhol (212) studied a
heterogeneous population of patients with pulmonary diseases and found a
significant increase of Z deficient phenotypes, particulary in patients
with bronchial asthma, chronic bronchitis, and pulmonary emphysema. In
33 subjects found later to have the ZZ phenotype, 23 presented in the
initial study of Eriksson (211) with chronic obstructive pulmonary
disease, which in 50% took the form of extensive pulmonary emphysema.
Several reports have confirmed the high incidence of pulmonary emphysema
in ZZ deficient subjects. Rawlings (213) described clinical repiratory
obstruction in 19 of 20 ZZ patients, which was confirmed by pulmonary
function testing in 18. Identical findings have been reported recently
by Eriksson (214).
'I'he question of whether COPD develops in patients wi th heterozygous
deficien~ phenotypes such as MZ remains controversial.
Mitmann (215)
indicated that intermediate APi deficien~ and MZ phenotypes occurred
lTK)re corrrrnonly than expected among patients with COPD. However, this
finding has been questioned in view of several reports in which neither
the prevalence of deficient phenotypes in patients with COPD (216-218)
nor the frequen~ of OOPO in subjects with deficient phenotypes was
found to be elevated (219,220). Nevertheless other documented reports
found a definite association (221,222). Differences in evaluation of pi
types in population samples or in the diagnosis of pulmonary disorders
could explain the discrepancies in these documented reports. The
incidence of other phenotypes in COPD is less well documented. One
report (222) indicated that MS heterozygotes do not seem to be
predisposed to pulr~nary diseases. The association of the S allele with
the Z allele is, according to Larsson (214), a strong predisposing
factor. Finally, the three cases in which a null phenotype of APi was
reported suffered from extensive pulmonary emphysema (223-225). These
findings strongly indicate that deficien~ of APi is the major cause of
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lung involvement in APi deficiency. The use of several experimental
anilnal models confirms the importance of a balance between protease and
antiprotease in the maintainance of lung integrity (226-234).
II.

Liver Diseases

A. Neonatal cirrhosis: Since the first report by Sharp (235) of
the association of neonatal jaundice and APi deficiency of the zz type,
several reports (236-239) have clearly established this relationship.
It appears that the presence of the Z allele is essential, but this
disorder can be found in the heterozygous state (240). The prognosis
associated with such liver diseases is not clearly established. In
contrast to at least one previous study (231), recent reports indicate
that the prognosis in these children is more hopeful. In a follow-up
survey of 18 patients presenting with this syndrome, Moroz et ala (242)
reported that 6 have died of cirrhosis, 3 have severe liver disease, but
11 have relatively little evidence of liver disease. Similarly a recent
study by Hadchovel (243) ex~ned the histological appearances in liver
biopsies obtained in the first six months of life from 15 children with
neonatal choleostasis of the zz type. The severity of the prognosis
appeared to be closely related to the histological picture. Five
patients reported by Hirschberger with neonatal hepatitis syndrome and
pi ZZ phenotype are all alive, and three are asymptomatic (244).
The proportion of children with the ZZ phenotype developing a
neonatal hepatitis syndrome has been debated. In an exhaustive study of
200,000 neonates in Sweden, Sveger (245) found 120 children with the zz
phenotype. Prolonged obstructive jaundice was found in 14, of which 9
had both clinical and laboratory evidence of severe liver disease, and 5
had only laboratory evidence of liver involvement. Eight others had
rrdnirnal laboratory abnormalities and variable clinical complaints.
Thus, the frequency of children with Pi zz presenting with liver
involvement at birth was only 16%. An additional factor is presumably
necessary for the development of liver disease. Conversely, two-thirds
of the children with cirrhosis following a history of neonatal hepatitis
are deficient in APi (Pi type ZZ) (246).
B. Adult cirrhosis in patients with zz pi type: This association
seems to be very frequent. In a previous study, Berg and Eriksson (247)
reported ex~nation of hepatic tissue in 14 ZZ patients. Cirrhosis and
fibrosis were clearly present in 8 cases. Additional reports have
confirmed this association (248,249). Nevertheless, a deficiency of APi
of z type does not seem to account significantly in the general etiology
of common cirrhosis (250).
III.

Other Diseases

Several other diseases or syndromes have been reported in
association with APi deficien~ of the Z type. They are indicated in
Table 25. Further studies will be necessary to determine whether these
associations are merely fortuitous.
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Table 25
Diseases or syndromes in which APi
deficiency has been reported
Disease or syndrome

Type of APi deficiency

Reference

Glomerulonephritis
Acne urticaria and
angioneurotic edema
·Biliary atresia
Ehlers-Dan1os syndrome
Chronic pancreatitis
Cystic fibrosis
Chromosome aberrations
Modificaton of
complement levels
\~ber-Christian syndrome
Rheumatoid arthritis
Nonatopic asthma
Spherocytosis
HefOC>chromatosis
Hepatoma

zz

251,252

Decreased serum levels
ZZ
pi null
MZ and ZZ
Decreased serum levels
variant pi types
Deficient Pi types

ZZ
MZ
Deficient Pi types
MZ
HZ and ZZ
lw1Z and ZZ

253,254
255,256
224,257,258
259,260
261
262-265

266,267
268,269
27'1,271
272

273
274
275-278

84

IV.

Personal Results

We present here our results on the frequen~ of deficient Pi types
in association with several clinical disorders.
Asthma in Children: A detailed report on this study in 298
children with asthma has already been published (279). The results can
be summarized as follows:
A.

1) Higher frequency of pi deficient phenotypes (I,S,P,Z), 22.5%, in
children with asthma as compared with 16.3% in a normal population of
the same geographic origin.
2) Greatly increased frequen~ of deficient phenotypes in nonatopic
asthma (46.2%). Normal incidence in atopic asthma (15.9%).
3) Significant effect of deficient phenotypes upon the age of
onset, the severi~ of the disease, the presence of hyperinflation, and
the existence of abnormalities of pulmonary function. The significance
of these results has been discussed (279).
B. Hemochromatosis: In primary idiopathic hemochromatosis the
incidence of hepatocellular carcinoma is high (280), and recently an
elevated frequency of the Z allele (60%) has been reported by Janus and
Carrell in 10 patients with this disease (276). We have therefore
undertaken Pi typing in a larger series of patients with primary
h~nochrornatosis from the Southeast and Midlands of England.
Since no
control figures using this technique are available from the same
geographical area, we have compared our results with those obtained from
two large series. The first, published by Cook, included healthy
subjects from the same regions but typed by acid-starch gel
electrophoresis (281), and the second consisted of a group of French
controls in whom pi types \~re determdned ~ isoelectric focusing (282)
(Table 26).
There was no significant difference in the distribution of the
various phenotypes between the patients and the two control series. In,
particular, we found the Z 'allele (MZ phenotype) in only one (2.5%) of
the 41 patients. This contrasts sharply with the figure of 60% found by
Janus and Carrell (276), suggesting that the Z allele is not a
predisposing factor, at least in our patients, in the initiation of the
disease or the subsequent develo~~ent of hepatocellular hepatoma.

c. Juvenile chronic polyarthritis: Breakdown of articular
collagen is an ~~rtant feature of arthritic joint damage (283), and
this in part appears to be due to an increased activity of synovial
collagenases (284,285). It is possible that deficient activity of
protease inhibitors could be a predisposing or aggrevating factor in the
pathophysiology of joint damage. An increased frequency of Z phenotypes
has been reported recently in adults with rheunatoid arthritis (286).
We have investigated the hypothesis that deficient alleles may be more
common in children with juvenile chronic polyarthritis (JCP). we
studied 96 patients with JCP. 1he criteria for the diagnosis were as
defined by Ansell (287): (a) onset before age 16; (b) involvement of
four or more joints for at least three months with pain and/or swelling
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Table 26

Occurrence of pi phenotypes in hemochromatosis
patients and controls
Subjects

Phenotype

Number
MS

M

HemochronB tosis
Controls (ref. 281)
Controls (ref. 282)

41
2786
1652

34

HZ
1

s

FM

1
(2.4%)

(2.4%)

(83%)

4
(10%)

(2.4%)

2464

225

48

(88%)

(8%)

(1. 7%)

(0.3%)

1362

185

43

23

(82%)

(11%)

(2.8%)

(1.4%)

8

1

24
(0.9%)
2
(0.1%)
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and/or limitations of movements; (c) if fewer joints are involved,
histology showing changes compatible with rheumatoid arthritis; and. (d)
exclusion of other disorders in the first year of disease, including
ankylosing spondylitis, psoriasis, ulcerative colitis, and systemic
lupus erythematosis. At the time of the blood sample, the mean age of
these 96 patients was 5.4 years (9 months - 15 years) and the
female:male ratio was 2.7 (7~ F : 26 M). Twenty had commenced as a
systerrdc illness going on to polyarthritis; chronic iridocyclitis was

present in 35 and amyloidosis in 20. A small number of cases had more
than one of these features, i.e., 2 with chronic iridocyclitis also had
amyloidosis. In 58 cases we also examined sera from the patient's
father and mother, and parentage in each case was confirmed by Qu, Am,
Inv, and HLA typing.
The distribution of APi phenotypes in JCP was compared (Table 27)
with that found in the two control series utilized for the
hemochromatosis study. The frequency of Z phenotypes was significantly
higher in the study gcoup than in controls (P < 0.001). The frequency
of the S phenotype was also elevated, although this difference was not
statistically significant. The distribution of the other phenotypes,
and in particular the Me allele, did not differ appreciably from control
values (Table 28)~
Tne genetic transmission of APi alleles was studied in 58 cases.
In the case of Sand Mc, alleles were inherited in random fashion
equally from mother and father, supporting the concept of autosomal
codorrdnant transmission (288). In contrast, the Z allele was
transmitted to the patient from the father in all but one family
(Table 29).

The striking abnormality in this study is the increased prevalence
of Z phenotypes in JCP. This is an important observation, since APi is
known to inhibit the activity of collagenases as well as neutral
proteases (see Chapter 3), which are involved in arthritic joint damage
(284), and APi levels in synovial fluids are elevated in some cases of
rheumatoid arthritis (289). In patients with deficient phenotypes,
however, the serum level of APi is much lower, and since this level
parallels the amount found in synovial fluid (289), the latter would be
expected to be markedly reduced. Since the mechanisms of inhibition
include formation of complexes between APi and proteases (290-292), low
levels of APi would result in increased amounts of protease remaining
unbound and active. Furthermore, we have shown that such unbound
proteases can act upon formed complexes causing their dissociation,
denaturation of APi, and the release of additional biologically active
protease (see Chapter 3). The increase of the S allele frequency,
although not significant, may also be involved in tile pathophysiology of
protease inhibition in JCP, since it is associated with decreased
amounts (20%) of serum APi (293).
The clinical relevance of this increase in Pi deficient phenotypes
is not clear. No difference in distribution of Pi types was apparent
when patients were subdivided with respect to clinical complications
such as amyloidosis, systemic involvement, and iridocyclitis, although
the frequency of S phenotypes was high in patients who had developed
amyloid. Similarly, an influence of deficient phenotypes on the age of
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Table 27

Comparison of APi distribution in juvenile chronic
polyarthritis and in two control populations
M

MS

MZ

FM

96

73.95

14.58

10.41

1.06

4565

88.50

8.00

1.60

0.70

1867

82.81

12.80

2.36

Number

JCP
(isoelectric focusing)

others

United Kingdom
controls (225)
(acid-starch gel)

1.20

French controls

(isoelectric focusing)

2.03

Table 28

pi distribution in juvenile chronic polyarthritis,
with particular respect to the presence of the Me allele
M

MS

McS

~IMc

Me

MZ

McZ

FM

96

57.29

13.56

1.04

15.62

1.04

9.37

1.04

1.04

1867

58.15

9.74

3.05

18.75

5.83

1.92

0.43

Number

JCP

French controls

Others

2.12

co
CD

89

Transmission of the
variant alleles

s
Me

z

Patients

Father

Mother

9

5

4

13

6

7

7

1
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disease onset is not evident in our study, and we did not find any
significant association between pi alleles and other genetic markers
(Qn, AIn, Inv, HIA), although the numbers studied may have prevented the
recognition of such a relationship. The result of our family study
revealed a predominantly paternal transmission of the Z allele.
Speculation concerning this interesting finding must await studies of
larger number of families.
JCP is the second rhellnatic disorder in which an elevated frequency
of deficient phenotypes of APi has been reported, but investigation of
other disease groups may reveal additional examples. Indeed, our
preliminary investigations show that the frequency of the Z allele is
also elevated in juvenile ankylosing spondylitis. Detenmination of pi
types may prove in the future to be useful in genetic counseling, as
well as in the diagnosis (e.g., we have found no increase in abnormal Pi
types in scleroderma), management, and prognosis of patients with
rheumatic disorders, in addition to providing further information
concerning the pathogenesis and the possible hereditary transmission of
these diseases.
D. Carcinoma of the lung: we have determined APi serum
concentrations and pi phenotypes in 123 patients (105 males, 18 females,
ages 29-84 years, mean age 62.8 years) from Lyon, France, presenting
with histologically proven squamous cell carcinoma of the lung. APi
serum concentration was determined by radial ~nodiffusion using
commercial plates (Behringwerke GMBH). The results in the cancer
population were compared with those obtained in healthy blood donors
from the Sru~ geographic area. The results of Pi phenotypes are
indicated in Table 30. In Table 31, the allele frequency in the two
populations is compared, and in Table 32 the rrean values of serum APi
are indicated. Statistical analysis of these results (294) indicates
that the frequency of MZ phenotypes is significantly increased (P <
0.05) in the squamous cell carcinoma population. Similarly, the
frequency of the z allele is significantly increased (P < 0.01). Study
of APi serum concentrations by analysis of variance indicated that
values in both non-MZ and MZ populations are significantly increased in
comparison with levels in normal subjects (P < 0.001), but this increase
is less in patients with MZ phenotypes than in patients with non-MZ
phenotypes {P < 0.00l}.

'l'he significantly higher proportion of heterozygous MZ deficient
phenotypes in patients presenting with squamous cell carcinoma of the
lung is a striking feature. In two recent publications (295,296) a
relatively high incidence of MZ phenotypes was reported in patients with
squamous cell carcinoma (8.7%) and with lung cancer (6.3%), but due to
the small number of cases studied, the values did not reach statistical
significance. calculation of the relative risk of squamous cell
carcinoma in our patients possessing a Z allele indicates that it is
3.05 times greater than the risk associated with the presence of other
alleles.
Several hypotheses could be proposed to explain this association:
(a) a genetic mechanism in which the Z allele could be linked with other
genetic factor(s) whose expression could be associated with a greater
susceptibility to this kind of cancer; or (b) a biochemical mechanism in
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Table 30
APi phenotypes in patients and controls
Subjects

Lung cancer
patients
Controls

. Phenotyp= distr ibution (%)

Number
'M

MS

MZ

s

sz

123

75.61

14.63

6.50

0.81

0.81

1.63

1867

82.81

12.80

2.36

0.70

0.16

1.17

Other
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Table 31

Distribution of APi Z phenotypes and of Z alleles
in lung cancer patients and controls
Subjects

Number

Phenotype distribution (%)

MZ,
Lung cancer
patients
Controls

sz

Allele frequency (%)

Other

Z

Other

123

7.31

92.69

3.65

96.35

1867

2.52

97.68

1.28

98.71
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Table 32
Serum levels of APi 1n lung cancer patients and controls
Subjects

Number

Serum APi (rng%)

Standard deviation

Lung cancer
patients

MZ
Other

8

299.6

110.8

115

419.5

177.9

30

167.2

33.2

320

218.5

57.3

Controls
MZ

Other

94

which APi deficiency would favor cell transformation. Indeed, in vitro
studies have demonstrated a role of proteases in cell division (297) . .
uncontrolled proliferation, and increased rragration of malignant cells
(298). Similarly, protease inhibitors have been reported to be capable
of inhibiting the growth of tumor cells {299,300}. The documented
increase of APi in malignant tumors (301) confirmed in this particular
study could be interpreted as an attempt of the organism to prevent or
restrain cell proliferation. It has been clearly demonstrated that in
patients possessing the Z allele serum APi does not increase in response
to exogenous stimuli, including vaccination (302) and estrogen
admdnistration (303), factors which normally double the serum
concentration of APi in subjects with nondeficient phenotypes. It is
tempting to speculate that in these patients APi deficiency could
represent a predisposing factor in the initiation of malignant cell
transformation ana/or in its subsequent proliferation.
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S~/~

AND CONCLUSION

In the first chapter, we discussed the different techniques now
available for precise determination of APi status. ~hasis was placed
on phenotype determination, using isoelectric focusing and complementary
print ~unofixation, with special attention to the analysis of the
latter using mdcrodensitornetry. Several pitfalls encountered during Pi
determination were discussed, as well as methods to overcome them.
Finally, a step-by-step procedure for precise deterrodnation of APi
status was outlined.
The second chapter was concerned with the study of the different
molecular variants of APi that represent the Pi system. Several new
variants -- Mb, Me, and I2 -- were described, and two original
investigations on the distribution of Pi types in more than 3000
individuals were reported. A correlation was drawn between the
expression of the different phenotypes and alleles and the resulting
serum APi values. Finally, the ~rtance of the Pi system as a genetic
marker was emphasized.
The third chapter was devoted to the study of the structure and
biological role of APi. Following a review of the present state of
knowledge of the structure of the APi molecule, including recent
evidence for amino acid substitutions responsible for APi polymorphism,
we presented personal studies on the role of sialic acid in APi
isoelectric heterogeneity and polymo~hism. After a brief review of the
biological role of APi as a protease inhibitor, we reported a study of
the binding of APi with elastase and t~sin. The results suggest that
in excess of enzyme the complex between APi and protease is attacked,
and that as a result the inhibitory effect of APi is completely
suppressed.
The fourth chapter dealt with the clinical relevance of APi
deficiency. TWo main types of disorders are known to be associated with
this deficien~, i.e., pulmonary and liver involvement. we reported
personal results describing the predisposing role of APi deficien~ in
nonatopic infantile asthma, in hemachromatosis, in squamous cell
carcinoma of the lung, and in rheumatoid arthritis. Prelirndnary data
concerning an association between deficient Pi phenotypes and
periodontal disease are also suggestive. All the data seem to indicate
that the clinical area in which APi deficien~ is ~plicated is much
wider than previously recognized. This fully justifies the objectives
of the study.
Several points need further investigation in association with APi
studies. ~be most intriguing is the basis for the microheterogeneity
and polymorphism of this protein, which will be solved only by
structural studies on the different components of each allele product.
Our preliminary results concerning APi-protease complexes are also
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particularly intriguing, and could explain the "hit-or-miss"
consequences of APi deficiency. The precise determination of the
effects of structural differences in APi molecules on the inactivation
of several proteolytic enzymes of biological importance remains to be
studied.

The discovery of several new disease states in which APi deficiency
seems to be strongly involved enhances further the interest of Pi
determination. It indicates the importance of systematic studies in
other classes of diseases in which a deficiency of this protein could
play an ~portant role as a predisposing factor.
In conclusion, the field of interest of APi covers several domains,
including fundamental biochemistry, genetics, and clinical research, and
many important studies remain to be carried out in each of these areas.

